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Adverse drug reactions (ADRs) are the most clinically significant and costly medication-related 
problems in nursing homes (NH), and are associated with an estimated 93,000 deaths a year and 
as much as $4 billion of excess healthcare expenditures.  Current ADR detection and 
management strategies that rely on pharmacist retrospective chart reviews (i.e., usual care) are 
inadequate.  Active medication monitoring systems, such as clinical event monitors, are 
recommended by many safety organizations as an alternative to detect and manage ADRs.  
These systems have been shown to be less expensive, faster, and identify ADRs not normally 
detected by clinicians in the hospital setting.  The main research goal of this dissertation is to 
review the rationale for the development and subsequent evaluation of an active medication 
monitoring system to automate the detection of ADRs in the NH setting.  This dissertation 
includes three parts and each part has its own emphasis and methodology centered on the main 
topic of better understanding of how to detect ADRs in the NH setting. 
 The first paper describes a systematic review of pharmacy and laboratory signals used by 
clinical event monitors to detect ADRs in hospitalized adult patients.   The second paper 
describes the development of a consensus list of agreed upon laboratory, pharmacy, and 
Minimum Data Set signals that can be used by a clinical event monitor to detect potential ADRs.  
The third paper describes the implementation and pharmacist evaluation of a clinical event 
monitor using the signals developed by consensus. 
DETECTING ADVERSE DRUG REACTIONS IN THE NURSING HOME SETTING 
USING A CLINICAL EVENT MONITOR 
  
Steven Mark Handler MD, MS, PhD 
University of Pittsburgh, 2010 
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The findings in the papers described will help us to better understand, design, and 
evaluate active medication monitoring systems to automate the detection of ADRs in the NH 
setting.  Future research is needed to determine if NH patients managed by physicians who 
receive active medication monitoring alerts have more ADRs detected, have a faster ADR 
management response time, and result in more cost-savings from a societal perspective, 
compared to usual care. 
 vi 
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1.0  INTRODUCTION 
1.1 MEDICATION USE IN NURSING HOMES 
Medications are commonly prescribed to nursing home (NH) residents with the goals of curing 
or palliating disease and improving quality of life.1  Nursing home residents are prescribed more 
medications than patients in any other medical setting because of the number and severity of 
chronic comorbid medical conditions.  Using data from 1997, nursing home residents take an 
average of 8.8 medications per day (7.6 regularly scheduled and 1.2 as needed) and nearly one-
third were prescribed >9 medications (the Centers for Medicare & Medicaid definition of 
polypharmacy).2   Using the most recently available data, the number of NH residents who are 
prescribed >9 medications has increased to 60.9%, as of 2005.3  Medication-related problems are 
a frequent consequence of polypharmacy. 
1.2 MEDICATION-RELATED PROBLEMS IN NURSING HOMES 
The terms adverse drug event and adverse drug reaction are often used interchangeably.  
Although interrelated, these terms represent distinct and measurable phenomena.  The definition, 
terminology, and measurement of adverse drug events (ADEs) and adverse drug reactions 
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(ADRs) in this proposal will follow the World Health Organization’s model 4-5 and the model of 
Naranjo et al. 6, depicted graphically below (Figure 1). 
 
Adverse Event
(AE)
Adverse Drug Event
(ADE)
Adverse Drug Reaction
(ADR)
 
Figure 1. World Health Organization/Naranjo Model of Adverse Drug Reactions. 
 
Adverse events (AEs) are negative patient events that are expressed as symptoms, signs or 
laboratory abnormalities.6  When a relationship between the adverse event and a drug is 
suspected and plausible, then an ADE is assumed.  When an ADE is determined to be causally 
related to a drug, then an ADR is assumed.  Thus, an ADR will be defined as a unintended or 
noxious responses to a drug given in a dosage intended for prophylaxis, diagnosis, or therapy.4-5  
In essence, the model delineates differing levels of certainty about the relationship of an adverse 
patient event to a drug. In our studies we will be using ADRs as the endpoint for all analyses. 
1.3 PUBLIC HEALTH SIGNIFICANCE AND IMPACT OF ADVERSE DRUG 
EVENTS IN NURSING HOMES 
Institutionalized elderly experience ADEs at a rate as high as 10.8 events per 100-patient months, 
often as a result of polypharmacy, multiple comorbid illness, and difficulty with monitoring 
prescribed medications.7-8  This translates into approximately 135 ADEs each year in an average 
size NH (bed size of 105) or approximately 2 million events a year among all U.S. NH patients.  
ADEs represent the most clinically significant and costly medication-related problems in NHs 
and are associated with 93,000 deaths a year and in as much as $4 billion of excess healthcare 
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expenditures.8-9  Excess healthcare expenditures associated with ADEs are usually a result of 
increased physician visits, ordering of additional medications or diagnostic studies, and the 
evaluation and management of patients in the emergency department or hospital setting.10-11  The 
frequency of ADEs will likely increase as the U.S. population ages and the demand for NH 
services increases from the current 1.6 million people receiving care in one of more than 16,000 
NHs to over 3 million people by 2030.12-13 
1.4 EPIDEMIOLOGY OF ADVERSE DRUG EVENTS IN NURSING HOMES 
Investigators have conducted epidemiological studies to attempt to identify a uniform set of 
patient-level risk factors for the development of ADEs in NHs in order to focus detection and 
prevention efforts on high-risk individuals.10-11, 14-18  These studies evaluated the effects of age, 
gender, time since admission, number of comorbid conditions, and number and type of 
prescribed medications.  Only the presence of polypharmacy (not uniformly defined throughout 
the studies) has consistently been found to increase the likelihood of developing an ADE.  The 
lack of easily identifiable patient characteristics has limited the development and implementation 
of efforts to detect and prevent ADEs in the NH.19 
1.5 SYSTEMS ANALYSIS OF ADVERSE DRUG EVENTS IN NURSING HOMES 
A systems analysis is the interdisciplinary part of science, dealing with analysis of sets of 
interacting entities, the systems, often prior to their automation as computer systems, and the 
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interactions within those systems.20-22 A systems analysis of ADEs suggest that as many as half 
of these events are preventable and that they are frequently a direct result of medication errors.7  
Medication errors are commonly defined as errors occurring in the medication use process (e.g., 
prescribing, order communication, dispensing, administration, and monitoring).23  Data about 
preventable ADEs in NHs suggest that most (70-80%) are associated with monitoring, rather 
than prescribing errors.10-11  Monitoring errors generally refer to inadequate laboratory 
evaluation of drug therapies or a delayed or failed response to signs or symptoms of drug toxicity 
or laboratory evidence of toxicity.  Based on the results of these and other studies,24-27 the term 
suboptimal medication monitoring has recently been introduced to explain a common pathway of 
systems failures that underlie monitoring errors causing ADEs in older adults.28 
1.6 LIMITATIONS OF CURRENT METHODS FOR DETECTING ADVERSE DRUG 
EVENTS 
Manual ADE detection techniques, including voluntary reporting through ADE, medication error 
or incident reports, direct observation of medication passes, and retrospective chart reviews have 
formed the foundation for the body of research underlying our current understanding of ADEs in 
the NH setting.  Although retrospective manual chart review is considered to be the criterion 
standard for ADE detection, it is time-consuming, costly, and impractical for routine clinical 
use.29-32 
Manual chart review is also the primary ADE case-finding technique for consultant 
pharmacists, who have a federal mandate to conduct monthly medication regimen reviews in 
NHs (i.e., usual care) and report their findings to the appropriate attending physician.33  
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Consultant pharmacist services have been required in NHs since 1974.34  The Centers for 
Medicare and Medicaid Services outlines the expectations of the NH’s consultant pharmacist in 
Appendix PP of the State Operations Manual that are used to guide and set minimal standards 
during annual state surveys.  The State Operations Manual mandates that the drug regimen of 
each patient must be reviewed at least once a month by a licensed consultant pharmacist who 
must report the presence of ADEs and recommend that a medication should be stopped, changed, 
or monitored more closely by the attending physician.35  The State Operations Manual further 
suggests that the reports made by a consultant pharmacist be acted on by the attending physician 
within 30 days. 
A significant limitation of pharmacist-conducted monthly medication regimen reviews is 
their retrospective nature, which has not been shown to improve clinical outcomes.36-37  
Retrospective chart reviews do not provide the attending physician with real-time notification of 
ADEs, and could result in notification delays of up to 30 days .19  Moreover, in a recent study, 
although attending physicians rated the two most important functions of consultant pharmacists 
as helping the NH comply with state and federal regulations, and monitoring the safety of all 
prescribed medication, physicians also rated these two functions as most in need of 
improvement.38 
1.7 ACTIVE MEDICATION MONITORING SYSTEMS FOR DETECTING 
ADVERSE DRUG EVENTS ARE RECOMMENDED 
The Institute of Medicine and other patient safety organizations recommend that all healthcare 
settings assess the safety of medication use through active monitoring systems within a culture of 
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safety.19, 35, 39-44  Nevertheless, the majority of health information technology interventions to 
improve patient safety with respect to medications have focused on enhancing prescribing 
through the use of with CPOE (computerized provider order entry) with CDS (clinical decision 
support).45-48  These CPOE with CDS interventions have had varying degrees of success in 
detecting and reducing ADEs in diverse clinical settings, including NHs.8, 49  Active medication 
monitoring systems are particularly needed to detect ADEs in priority populations such as 
institutionalized elderly.  This is because of long-standing concern about the quality of their 
pharmaceutical care, presence of polypharmacy, and the limited ability of the NH workforce to 
monitor prescribed medications effectively due to an insufficient healthcare personnel, high staff 
turnover, and a poorly developed safety culture.2, 50-54 
1.8 ACTIVE MEDICATION MONITORING SYSTEMS ARE OPTIMAL FOR 
DETECTING ADVERSE DRUGE EVENTS 
Computerized clinical event monitors, a type of active medication monitoring system, can detect 
ADEs via the processing of signals for laboratory test results and pharmacy orders.31, 55-56  
Compared with manual methods of ADE detection, hospital studies indicate that clinical event 
monitors, which provide feedback to healthcare professionals based on information available in 
electronic format, are less expensive, faster, and can identify ADEs not normally detected by 
clinicians.30, 57-61  Clinical event monitor systems have also been shown in certain studies to 
prevent the development, progression, or mitigate the seriousness of ADEs by promoting the 
early detection and appropriate response to events in evolution in the hospital and ambulatory 
care settings.32, 62-68  Despite the proven benefits of clinical event monitors on improving 
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healthcare quality and efficiency while reducing cost, few healthcare organizations have 
implemented and formally evaluated them.41-42, 49, 69  When used, these active medication 
monitoring systems have been implemented in non-standardized ways that make it difficult to 
reproduce findings and compare their effectiveness across patients and healthcare settings.39, 70  
This lack of generalizability contributes to the suboptimal detection and management of ADEs in 
U.S. hospitals and ambulatory care settings.71  
1.9 BARRIERS TO USING ACTIVE MEDICATION MONITORING SYSTEMS IN 
NURSING HOMES 
Studies have been conducted to assess the adoption and barriers to implementing health 
information technology such as active medication monitoring systems in a variety of clinical 
settings including NHs.72-73  These studies suggest that NHs are the farthest behind in the 
adoption of health information technology.  Moreover, when health information technology is 
available, it is used primarily for state or federal payment and certification requirements.  There 
is minimal use of clinical health information technology applications, and when used, these 
systems are usually not integrated.  Nevertheless, almost all NHs generate laboratory, pharmacy, 
and Minimum Data Set data (MDS; a standardized summary assessment instrument required for 
all NH patients) in electronic format as a byproduct of other work processes.  Studies to assess 
barriers to the use of health information technology in the NH setting74-75 have concluded that 
multiple stakeholders would incur the costs of implementing and maintaining these systems, but 
that these costs would likely not be fully aligned with their benefits.  In addition to concerns 
about cost, other barriers include difficulty in finding health information technology producers 
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that meet their needs, lack of evidence that health information technology will have a positive 
impact on quality of care and operational efficiencies (e.g., alert burden), and lack of the 
hardware or technical support to access and use the electronic data that they generate.76-77 
1.10 SUMMARY AND OBJECTIVE OF DISSERTATION 
ADEs among NH patients are common and costly problems that are likely to increase 
substantially as the U.S. NH population grows.  A lack of easily identifiable patient-specific risk 
factors makes it difficult to routinely detect these events.  Systems analyses of ADEs suggest that 
suboptimal medication monitoring is the most common pathway underlying these events in the 
NH.  Current strategies that rely on voluntary reporting, such as incident reports, direct 
observation of medication passes, and retrospective chart review are time-consuming, costly, and 
impractical for routine clinical use.  Several prominent quality improvement organizations 
recommend active medication monitoring systems as a potential solution to improving 
medication safety.  Active medication monitoring systems are particularly needed to detect 
ADRs in priority populations such as institutionalized elderly because of the long-standing 
concern about the quality of their pharmaceutical care.  Although NHs have yet to adopt a 
significant amount of health information technology, the majority generate laboratory, pharmacy, 
and Minimum Data Set data in electronic format that can be used by active medication 
monitoring systems such as clinical event monitors to automate the detection of ADEs.  The 
main research goal of this dissertation is to review the rationale for the development and 
subsequent evaluation of an active medication monitoring system to automate the detection of 
ADRs in the NH setting. 
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1.11 CONTRIBUTION OF DISSERTATION 
In a comprehensive review of medication-related adverse events in nursing homes, Handler et al. 
reported that there was substantial variability in the incidence of ADEs, ranging from 1.19 to 
7.26 per 100 resident-months.7  The authors concluded that the variability in the incidence of 
ADEs was most likely due to the lack of uniformity in case-finding techniques.  In particular, 
Gurwitz et al.11 reported the highest incidence rate, which was greater than four times higher 
than the rate in their previous study.10  The significant increase in the incidence of ADEs was 
attributed to the investigators using a previously developed clinical event monitor system that 
had been developed for use in the hospital setting. 
The overall goal of my research has been to expand on our previous knowledge by 
developing and testing a clinical event monitor system specifically designed for detecting ADRs 
in the NH setting.  The first step was to conduct a systematic review of hospital-based clinical 
event monitor systems to better understand the universe of signals used to detect ADEs and how 
to calculate and compare their respective performance characteristics using positive predictive 
values.  The second step was to develop NH-specific signals for ADR detection by conducting a 
modified Delphi survey of experts in geriatrics.  The third step was to assess the performance 
characteristic of a NH-specific clinical event monitor system that uses the signals derived by 
expert consensus.  To the best of my knowledge, no previous research has been published on the 
development of a consensus list of signals and/or the evaluation of an active medication 
monitoring system to automate the detection of ADRs in the NH setting. 
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1.12 ORGANIZATION OF DISSERTATION 
The remainder of the dissertation is divided into four chapters including three papers (chapters 2, 
3, and 4), followed by a summary of findings, their significance, and direction of future research.  
Each paper has its own method centered on the theme of development and evaluation of an 
active medication monitoring system to automate the detection of ADRs in the NH setting.  The 
first paper describes a systematic review of pharmacy and laboratory signals used by clinical 
event monitors to detect ADEs in hospitalized adults.  This paper has been published in the 
Journal of the American Medical Informatics Society.60  The second paper describes the 
development of a consensus list of agreed upon laboratory, pharmacy, and Minimum Data Set 
signals that can be used by a clinical event monitor to detect potential ADRs.  This paper has 
been published in the Journal of the American Geriatrics Society.78  The third paper describes the 
implementation and pharmacist evaluation of a clinical event monitor using the signals 
developed by consensus.  This paper has been published in the American Medical Informatics 
Association Annual Symposium Proceedings.79 
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2.0  A SYSTEMATIC REVIEW OF THE PERFORMANCE CHARACTERISTICS OF 
CLINICAL EVENT MONITOR SIGNALS USED TO DETECT ADVERSE DRUG 
EVENTS IN THE HOSPITAL SETTING 
2.1 ABSTRACT 
2.1.1 Objective 
Despite demonstrated benefits, few healthcare organizations have implemented clinical event 
monitors to detect adverse drug events (ADEs).  The objective of this study was to conduct a 
systematic review of pharmacy and laboratory signals used by clinical event monitors to detect 
ADEs in hospitalized adults. 
2.1.2 Design 
We performed a comprehensive search of MEDLINE, CINHAL, and EMBASE to identify 
studies published between 1985 and 2006.  Studies were included if they: described a clinical 
event monitor to detect ADEs in an adult hospital setting; described laboratory or pharmacy 
ADE signals; and provided positive predictive values (PPVs) or information to allow the 
calculation of PPVs for individual ADE signals. 
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2.1.3 Measurements 
We calculated overall estimates of PPVs and 95% confidence intervals (CIs) for signals reported 
in 2 or more studies and contained no evidence heterogeneity. Results were examined by signal 
category: medication levels, laboratory tests, or antidotes. 
2.1.4 Results 
We identified 12 observational studies describing 36 unique ADE signals. Fifteen signals (3 
antidotes, 4 medication levels, and 8 laboratory values) contained no evidence of heterogeneity.  
The pooled PPVs for these individual signals ranged from 0.03 [CI=0.03-0.03] for hypokalemia, 
to 0.50 [CI=0.39-0.61] for supratherapeutic quinidine level. In general, antidotes (range=0.09-
0.11) had the lowest PPVs, followed by laboratory values (0.03-0.27), and medication levels 
(0.03-0.50). 
2.1.5 Conclusion 
Results from this study should help clinical information system and computerized decision 
support producers develop or improve existing clinical event monitors to detect ADEs in their 
own hospitals by prioritizing those signals with the highest PPVs. 
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2.2 INTRODUCTION 
Clinical decision support (CDS) systems have been shown to improve patient care and treatment 
outcomes by providing physicians and other healthcare providers with patient-specific 
information that is intelligently filtered and presented at appropriate times.71  Clinical event 
monitors, one of the most common types of CDS systems, provide feedback through alerts and 
reminders to healthcare providers when triggered by certain information available in electronic 
format (i.e., by signals).80  Clinical event monitors can be used to detect medication-related 
problems by processing pharmacy order signals81-82 and laboratory test result signals,83 generated 
by systems with varying levels of automation and sophistication.30 
The most clinically significant medication-related problems are adverse drug events 
(ADEs).  Various definitions have been proposed and used throughout the literature to describe 
ADEs.  For this paper, we use the Institute of Medicine definition which defines ADEs as 
“injuries resulting from a medical intervention related to a drug.”7, 39, 84  ADEs are common and 
occur in 2.4-5.2 per 100 hospitalized adult patients.29, 85-87  A meta-analysis of fatal ADEs 
suggest that these events are between the fourth and sixth leading cause of death in the U.S.88  
Each ADE is estimated to increase the length of hospital stay by 2.2 days and to increase the 
hospital cost by $3,244.89 
Compared with manual methods of ADE detection (e.g., chart review or voluntary 
reporting), clinical event monitors are less expensive and faster, and they often identify ADEs 
not normally detected by clinicians during the course of routine hospital care.57, 61, 90-91  Through 
the early detection and prevention of ADEs, clinical event monitors can improve the quality of 
care, while reducing health care costs by as much as $760,000 per year in a teaching hospital.62, 
92-94  Despite the potential benefits of clinical event monitors and the fact that several prominent 
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national organizations have recommended their use to detect ADEs,41-42 few healthcare systems 
have implemented them.49  Moreover, when they have implemented them, they have done so in 
non-standardized ways that make it difficult to compare and synthesize the results.23, 70  The lack 
of generalizability of results in turn contributes to the problems and suboptimal performance of 
hospitals in the U.S. healthcare system.71 
To begin to address these concerns and to help clinical information system and CDS 
producers develop, select, or improve, systems to detect ADEs, we conducted a systematic 
review of individual pharmacy and laboratory signals that are currently used by clinical event 
monitors to detect ADEs in the adult hospital setting.  When possible, we calculated the positive 
predictive values (PPVs) of individual signals. 
2.3 METHODS 
2.3.1 Study Identification and Eligibility 
Before we implemented our literature search, we established criteria for inclusion and exclusion 
of studies.  We included studies that met the following four criteria: their results were published 
between January 1, 1985, and July 1, 2006; they described a clinical event monitoring system to 
detect ADEs in an adult hospital setting; they described laboratory or pharmacy ADE signals; 
and they provided PPVs or information to allow the calculation of PPVs for individual ADE 
signals.  We excluded studies if they focused on ADE prevention rather than detection (e.g., if 
they focused on computerized physician order entry systems) as this has recently been reviewed 
elsewhere.95  We also excluded studies if they described non-laboratory or non-pharmacy ADE 
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signals, including signals to monitor physiologic data (e.g., blood pressure or heart rate) or 
administrative data (e.g., diagnostic or procedural codes [ICD-9 or CPT]), or if they described 
free-text search strategies to detect potential ADEs.  Because of concerns that non–peer-
reviewed data might introduce bias into our systematic review,96-97 we also excluded studies in 
which data was presented as an abstract, poster presentation, or editorial. 
2.3.2 Information Sources and Search Strategy 
We searched OVID MEDLINE, OVID CINHAL, and EMBASE for articles published in all 
languages between January 1, 1985, and July 1, 2006.  In OVID, we searched for the following 
medical subject headings (MeSH) keywords, and text words: adverse drug event, adverse drug 
reaction, adverse drug reaction reporting systems, clinical event monitor, clinical decisions 
support systems, clinical laboratory information systems, clinical pharmacy information system, 
computer generated signals, decision support system, drug monitoring, medication errors, and 
physiologic monitoring.  In EMBASE, we searched for the above terms plus the following 
EMTREE keywords: computer assisted drug therapy and drug surveillance program.  We 
supplemented the computerized search by reviewing the reference lists of all articles selected for 
inclusion. 
2.3.3 Study Selection, Data Extraction and Review Criteria 
Two reviewers (SH and RA) independently assessed each article for eligibility criteria, with 
adjudication by a third reviewer (JH) in cases of disagreement.  While reviewing each study that 
met the eligibility criteria, the same two authors (SH and RA) used standardized forms to 
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independently extract and record: hospital characteristics (e.g., teaching or community hospital, 
number of beds); patient characteristics (e.g., number of patients included); the signals monitored 
by the hospitals; and, data necessary to record or calculate positive predictive values.  To collect 
the necessary data to calculate a PPV, we reviewed the data from each signal in the individual 
included studies.  For every signal in an included study, we recorded the number of times that a 
specific signal fired and the number of times that a health professional determined that the signal 
represented an ADE.  Study authors were contacted by email for data clarification when 
necessary. 
Signals from each of the studies that met eligibility criteria were included and combined 
if they measured the same parameter (e.g., digoxin level, serum potassium level, or use of 
vitamin K) independent of the reference interval or dosage used in the particular study.  Signals 
were then grouped into one of three categories: antidote signals (triggered by administration of 
medications given to counteract the effects of a poison, toxin, or other agent with toxic effects), 
medication level signals (triggered by elevated, or supratherapeutic, drug levels), and laboratory 
result signals (triggered by abnormal values in blood tests). 
2.3.4 Quantitative Data Synthesis and Statistical Analysis 
To calculate a study-specific PPV for each signal, we divided the number of times that a signal 
fired and an ADE was confirmed (i.e., the number of true-positives), by the number of times the 
signal fired with or without an ADE being confirmed (i.e., the sum of true-positives and false-
positives).  PPVs were chosen as the performance characteristic of interest since the majority of 
studies conducted a targeted verification of signal firings and did not include a corollary gold-
standard measure, such as an independently conducted chart review looking for the presence of 
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ADEs.  As a result, the sensitivity and specificity of individual signals used to detect ADEs could 
not be calculated. 
To determine the appropriateness of computing a pooled PPV, we compared the 
individual study-specific PPVs using the chi-square test for homogeneity of proportions.98  For 
those signals which there was no evidence of heterogeneity (p>0.05) we calculated an overall 
estimate of pooled PPVs and corresponding 95% confidence intervals (CIs).  We used a 
generalized estimating equations (GEE) model by combining the PPVs for signals reported in at 
least two studies.  This model included an exchangeable correlation structure to account for 
within-study correlation, using the total number of signal firings in each study as the weighing 
factor.99-101  We also examined the sensitivity of the overall PPV estimates using a fixed effects 
model recommended in the meta-analytic literature.102 
To determine whether certain studies were heavily influencing the overall PPV estimate 
for each signal, we performed an influence analysis in which we excluded studies, one at a time, 
and reestimated the overall PPVs.  We also examined the cumulative effect on the overall PPV 
estimate by adding studies, one at a time, ordered by year of publication, and hospital bed size.  
If there were any publication bias, it would most likely be caused by the greater probability of 
publication of studies with a larger number of firings or of studies with a smaller number of 
firings but a greater PPV.  We examined this possibility by visually inspecting a scatter plot of 
the PPV and the square root of the number of signals (which is proportional to the reciprocal of 
the standard error) and testing for a significant linear trend between them.  If we found a lack of 
data points near the origin or a statistically significant negative linear trend, we would consider it 
to be evidence of publication bias.103  We conducted all statistical analyses with either SAS 
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version 8.2 for Windows (SAS Institute, Inc., Cary, NC) or Stata version 9.0 for Windows 
(StataCorp, LP, College Station, TX). 
2.4 RESULTS 
Of the 6649 titles that were initially identified, 4243 were from MEDLINE, 859 were from 
CINHAL, and 1547 were from EMBASE.  After removing duplicates and going through a 
thorough screening process (Figure 2), we identified 12 observational studies that met our 
eligibility criteria.56-57, 64, 66, 68, 104-111   Table 1 lists the 12 studies and the characteristics of the 
study sites.  All but two of the studies were conducted in teaching hospitals. 
Unique titles identified for title review (n = 6399)
Articles screened (n= 354)
Rejected on title review (n = 5417)
Titles considered relevant (n = 982)
Rejected on abstract review (n = 628)
Rejected on article review (n = 342)
Articles included (n =12)
Titles identified for title review (n = 6649)
Rejected as duplicates (n = 250)
 
Figure 2. Flow diagram of included and excluded studies. 
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Table 1. Characteristics of studies included in the systematic review. 
Author/Year/Reference Study Site 
Evans et al, 1991 104 500-bed tertiary teaching hospital 
Azaz-Livshits et al, 1998 105 34 bed medical ward in teaching hospital 
Jha et al, 1998 56 726 bed tertiary teaching hospital 
Raschke et al, 1998 64 650 bed community teaching hospital 
Levy et al, 1999 57 34 bed medical ward in teaching hospital 
Dormann et al, 2000 107 9 bed medical ward in a teaching hospital 
Brown et al, 2000 111 238 bed Veterans Administration Medical Center 
Jha et al, 2001 108 726 bed tertiary care teaching hospital 
Thuermann et al, 2002 109 86 bed neurology department in teaching hospital 
Dormann et al, 2004 110 29 bed gastroenterology ward in teaching hospital 
Silverman et al, 2004 66 726 bed tertiary care teaching hospital 
Hartis et al, 2005 68 1,952 beds in six community hospitals 
 
Of the total of 36 signals that we identified in two or more publications and included in our 
analysis, 7 were administrations of antidotes, 10 were supratherapeutic medication levels, and 19 
were abnormal laboratory test results.  Fifteen signals (3 antidotes, 8 laboratory tests, and 4 
medication levels) contained no evidence of heterogeneity (p>0.05) and were pooled to calculate 
overall PPVs and 95% CIs.  Naloxone was not included in the analysis because of the 12 studies 
that met eligibility criteria, only one study provided sufficient information about naloxone to 
calculate PPVs.37  Because we could not calculate a pooled PPV (our primary unit of analysis) 
with the PPV from only one study, naloxone was not included in our systematic review. 
   
Of the antidote signals (Table 2), sodium polystyrene administration, had the lowest pooled PPV 0.09 (95% CI, 0.06–0.13), 
and metronidazole or vancomycin administration had the highest 0.11 (95% CI, 0.06–0.20). 
 
Table 2. Signals associated with antidotes. 
Signal* 
Number 
of Studies 
PPV 
Range 
P-value 
Test for 
Heterogeneity 
Overall Estimate 
of  PPV† 
(95% CI) 
Overall Estimate 
of PPV‡ 
(95% CI) 
Vitamin K given 3 0.02 – 0.30 < 0.01 - - 
Activated charcoal given 2 0.08 – 0.45 0.03 - - 
Antihistamine (e.g., diphenhydramine or 
hydroxyzine) given 
3 0.03 – 0.14 < 0.01 - - 
Oral metronidazole or vancomycin given 
2 0.07 – 0.16 0.06 0.11 (0.06–0.20) 
0.10 (0.06 – 
0.14) 
Antidiarrheal (e.g., loperamide, 
diphenoxylate, bismuth) given 
3 0 – 0.11 0.06 0.09 (0.07–0.13) 
0.07 (0.00 – 
0.15) 
Sodium polystyrene (Kayexalate®) given 
3 0.06 – 0.12 0.44 0.09 (0.06–0.13) 
0.08 (0.05 – 
0.12) 
   
Oral or topical steroids (e.g., prednisone, 
prednisolone) given 
2 0.04 – 0.09 < 0.01 - - 
* Naloxone not included as data was available from only a single study; †PPV calculated using GEE pooled estimate and CI; 
‡PPV calculated using fixed effects pooled estimate and CI 
 
Of the laboratory test result signals (Table 3), hypokalemia had the lowest pooled PPV 0.03 (95% CI, 0.03–0.03), and hypoglycemia 
had the highest 0.28 (95% CI, 0.24–0.32). 
 
   
Table 3. Signals associated with laboratory test results. 
Signal 
Number 
of Studies 
PPV 
Range 
P-value 
Test for 
Heterogeneity 
Overall Estimate 
of PPV† 
(95% CI) 
Overall Estimate 
of PPV‡ 
(95% CI) 
Serum creatinine elevated or increasing 5 0.08 – 0.39 <0.01 - - 
Hypoglycemia (as indicated by low or 
decreasing glucose) 
2 0 – 0.33 0.49 0.27 (0.27–0.27) 0.10 (0.00 – 0.27) 
Hyperbilirubinemia (as indicated by high or 
increasing bilirubin) 
4 0.05 – 0.39 < 0.01 - - 
Hyponatremia (as indicated by low or 
decreasing sodium) 
2 0.24 – 0.33 0.72 0.25 (0.23–0.28) 0.25 (0.09 – 0.41) 
Blood urea nitrogen (BUN) elevated or 
increasing 
3 0 – 0.30 0.41 0.22 (0.14–0.32) 0.17 (0.08 – 0.26) 
Eosinophilia (as indicated by high or 
increasing eosinophils) 
5 0 – 0.62 < 0.01 - - 
Hyperkalemia (as indicated by high or 
increasing potassium) 
5 0 – 0.67 < 0.01 - - 
   
Alanine aminotransferase (ALT) elevated or 
increasing 
3 0.12 – 0.38 < 0.01 - - 
Anemia (as indicated by a low or decreasing 
hemoglobin/hematocrit) 
5 0.12 – 0.30 0.14 0.19 (0.12–0.29) 0.16 (0.11 – 0.22) 
Partial thromboplastin time (PTT) elevated or 
increasing 
3 0.04 – 0.92 < 0.01 - - 
Gamma-Glutamyl Transferase (GGTP) 
elevated or increasing 
4 0.03 – 0.19 0.03 - - 
Alkaline phosphatase (ALP) level elevated or 
increasing  
5 0 – 0.31 < 0.01 - - 
Aspartate aminotransferase (AST) elevated or 
increasing 
4 0.01 – 0.23 < 0.01 - - 
Agranulocytosis or leukopenia (as indicated 
by low or decreasing white blood cells) 
4 0.09 – 0.5 0.15 0.11 (0.07–0.17) 0.10 (0.04 – 0.15) 
International normalized ratio (INR) elevated 
or increasing 
4 0.05 – 1.0 < 0.01 - - 
   
Lactate dehydrogenase (LDH) elevated or 
increasing 
3 0.02 – 0.17 0.06 0.06 (0.02–0.14) 0.03 (0.00 – 0.06) 
Thrombocytopenia (as indicated by low or 
decreasing platelets) 
4 0.03 – 0.12 0.01 - - 
Hypocalcemia (as indicated by low or 
decreasing calcium) 
2 0 – 0.11 0.25 0.06 (0.02–0.18) 0.02 (0.00 – 0.08) 
Hypokalemia (as indicated by low or 
decreasing potassium) 
2 0 – 0.03 0.86 0.03 (0.03–0.03) 0.03 (0.01 – 0.04) 
PPV= positive predictive value; †PPV calculated using GEE pooled estimate and CI; ‡PPV calculated using fixed effects pooled 
estimate and CI 
 
Of the medication level signals (Table 4), cyclosporine had the lowest pooled PPV 0.03 (95% CI, 0.02–0.06) and quinidine had the 
highest 0.50 (95% CI, 0.39–0.61).  Among the pooled signals considered, the antidote category had the lowest PPVs (range= 0.09-
0.11), followed by the laboratory test result category (range= 0.03-0.27), and the medication level category (range= 0.03-0.50). 
   
Table 4. Signals associated with supratherapeutic medication levels. 
Signal 
Number 
of Studies 
PPV 
Range 
P-value 
Test for 
Heterogeneity 
Overall Estimate 
of PPV† 
(95% CI) 
Overall Estimate 
of PPV‡ 
(95% CI) 
Quinidine 2 0.43 – 0.60 0.56 0.50 (0.39–0.61) 0.50 (0.22 – 0.78) 
Phenobarbital 3 0 – 1.0 < 0.01 - - 
Theophylline trough 5 0.25 – 1.0 0.01 - - 
Vancomycin peak or trough levels 3 0.18 – 0.33 0.31 0.26 (0.22–0.32) 0.26 (0.20 – 0.32) 
Procainamide 3 0 – 0.42 <0.01 - - 
Lidocaine 3 0.17 – 0.50 0.51 0.19 (0.17–0.21) 0.18 (0.09 – 0.28) 
Aminoglycoside antibiotic 3 0.04 – 1.0 < 0.01 - - 
Digoxin 8 0.08 – 1.0 < 0.01 - - 
Phenytoin 7 0.07 – 1.0 < 0.01 - - 
Cyclosporine 2 0 – 0.04 0.29 0.03 (0.02–0.06) 0.03 (0.00 – 0.06) 
PPV= positive predictive value; †PPV calculated using GEE pooled estimate and CI; ‡PPV calculated using fixed effects pooled 
estimate and CI 
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There were no meaningful differences in overall PPV estimates calculated with GEE models or 
fixed effects models.  The influence analysis suggested that the removal of certain studies 
affected the PPVs for particular signals.  For example, when the Evans et al. study was removed 
from the analysis of the signal for agranulocytosis or leukopenia, the pooled PPV increased from 
0.11 to 0.23.104  Similarly, when the Theurmann et al. study was removed from the analysis of 
the anemia signal, the PPV increased from 0.19 to 0.26.112  No effects were noted on the overall 
PPV estimates when stratified by study year or bed size. 
Some evidence of publication bias was found for the signal agranulocytosis or 
leukopenia.  Specifically, a significant negative association between the number of firings and 
the PPV (p<0.05), suggesting the possibility that smaller studies with lower PPVs may not have 
been published and may therefore have eluded our systematic review.  For the remaining signals, 
we found no evidence of publication bias. 
2.5 DISCUSSION 
This systematic review analyzed the performance characteristics of individual pharmacy and 
laboratory signals that are currently used by clinical event monitors to detect ADEs in the adult 
hospital setting.  Our review of the PPVs of 36 signals from 12 studies published between 1985 
and 2006 revealed two important findings. 
First, there was evidence of significant between-study heterogeneity for the majority of 
signals, limiting our ability to pool the PPVs of signals across studies.  Of the 36 signals 
identified in two or more publications, 21 contained evidence of heterogeneity and could 
therefore not be pooled to calculate overall PPVs.  There are at least two plausible explanations 
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for this heterogeneity.  First, it may be due to the use of different reference intervals for 
therapeutic medication levels and laboratory values in different studies.  Second, it may be 
attributable to the different hospital and/or patient characteristics which affect the underlying 
prevalence of ADEs.  This is particularly important because PPVs are by definition affected by 
the underlying prevalence of the condition of interest. 
The second important finding was that there was significant variability in the PPVs for 
different individual signals, both across studies and within signal categories (e.g., antidotes, 
medication levels, and laboratory test results).  The overall PPV estimates for the 15 pooled 
signals in the analysis ranged from 0.03 for hypokalemia to 0.50 for a supratherapeutic quinidine 
level.  Moreover, antidotes had the lowest PPVs, followed by laboratory test results, and 
medication levels.  It is not surprising that PPVs were highest for medication levels.  For this 
category of signal, the prior odds of an ADE are increased, since the underlying assumption is 
that patients in each case are already receiving the medication of interest and their prescribing 
clinicians are aware of the possibility of an ADE.113  In contrast, the other two categories of 
signals would not necessarily be expected to be associated with an ADE.  Laboratory values are 
often abnormal because of the onset or worsening of medical conditions unrelated to the use of 
medications.  Likewise, the majority of antidotes analyzed in our study can be used to treat 
multiple medical conditions, only a fraction of which are related to the presence of an ADE. 
2.5.1 Limitations and Strengths 
Our systematic review has several limitations that deserve mention.  First, systematic reviews of 
effect sizes often limit their selection of studies to those involving randomized controlled trials 
(RCTs).114  However, analyzing RCTs is not always feasible or preferable for evaluating the 
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performance characteristics of individual signals used to detect ADEs.115-116  For purposes of our 
analysis, we did not limit our systematic review to RCTs, so we were not able to apply 
instruments commonly used to assess the quality of RCTs.117-118  Second, although we found 12 
studies that could be included in the overall analysis, we found few studies that covered each 
ADE signal.  This may have limited our ability to identify the dependence of overall PPVs on 
factors such as facility bed size and to detect publication bias, a problem to which all systematic 
reviews are susceptible.119-120  Third, our analysis focused on data that is widely available in 
electronic format (such as laboratory and pharmacy information) and was thus biased against 
data that cannot be readily computed.  It also excluded some sources of electronic data available 
to enhance ADE detection, such as administrative data (e.g., ICD-9 and CPT codes), allergy 
rules, and free-text searching of clinician progress and discharge notes.31 
Despite these limitations, we believe that our results are important and represent the most 
comprehensive information available on the performance characteristics of ADE signals in the 
adult hospital setting.  Our analysis employed the "best practice" methods recommended for 
conducting systematic reviews of the literature.114  Moreover, in keeping with suggestions of the 
Roadmap for National Action on Clinical Decision Support, the study was designed to capture, 
organize, and assess studies available internationally.71  
2.5.2 Implications 
While the benefits of health information technology are clear at least in theory, adapting 
information systems to healthcare has proven difficult, partly because there are so many non-
standardized and independent approaches to creating and representing clinical knowledge and 
clinical decision support systems.73, 121  In this regard, our systematic review may provide a 
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foundation for and influence the future design and implementation of computerized decision 
support systems used to detect ADEs in the hospital setting.  Having comprehensive information 
on the performance characteristics of individual signals may help hospitals prioritize the signals 
to be included in their systems to maximize the detection of ADEs and to minimize the number 
of false-positive alerts (i.e., alert burden), which is a growing problem.76, 122  To further reduce 
false-positive alerts, investigators have also begun to integrate data from multiple sources, 
including pharmacy, laboratory, and demographic data.123-124  Taking the false-positive rate into 
account is especially important when large-scale information systems are being developed, since 
as many as 30% of information system projects fail and a significantly larger number have cost 
overruns.125 
The fact that many of the signals to detect ADEs have relatively low PPVs should not 
impede the adoption of clinical event monitors.126  In many respects, the monitors can be treated 
as a type of screening test that allows for early ADE identification and intervention, and thereby 
reduces morbidity and mortality rates.127  Indeed, the monitors have been shown to detect ADEs 
not normally detected by clinicians during the course of routine care, and to decrease the length 
of time until diagnosis and treatment.57, 61, 128  Screening tests such as fecal occult blood testing to 
detect colorectal cancer are recommended despite having PPVs that range from 0.02 to 0.18 in 
adults over 50 years old, and are thus similar to the ranges of some signals described in our 
study.129 
2.5.3 Recommendations for Future Work 
Additional studies are needed to improve the performance characteristics of individual ADE 
signals and clinical decision support systems, apply these systems to other clinical environments, 
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develop interoperable systems, and perform economic analyses of these systems.  Studies have 
suggested that ADE detection rates can be improved by combing multiple data sources and 
having a better understanding of the context of the data as they relate to patients' underlying 
medical conditions.130-133  Investigators have begun to use clinical decision support systems to 
detect ADEs in other clinical care settings, such as ambulatory care clinics and nursing homes.11, 
31, 134-135  These systems may be particularly useful in the nursing home setting where patients are 
frail, have multiple comorbid medical conditions, and take more medications per patient than in 
any other clinical setting.2, 11, 136  Since most systems lack standardized methods to export or 
share ADE algorithms, additional studies are required to develop interoperable systems.137-138  
Additional cost-benefit and cost-effectiveness studies are needed not only to determine the 
rational selection, optimal use, and potential success of systems used to detect ADEs, but also to 
determine the costs of developing and maintaining the systems and of responding to true-positive 
and false-positive alerts. 
2.6 CONCLUSIONS 
Our systematic review provides the PPVs of pharmacy and laboratory signals used to detect 
ADEs in the adult hospital setting, and suggests that the PPVs of individual signals vary widely.  
Our findings should help clinical information system and clinical decision support producers 
create and modify clinical decision support systems to detect ADEs in their own institutions.  
Future studies are needed to improve the performance characteristics of individual ADE signals 
and clinical decision support systems, apply these systems to other clinical environments, 
develop interoperable systems, and perform economic analyses of the systems. 
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3.0  CONSENSUS LIST OF SIGNALS TO DETECT POTENTIAL ADVERSE DRUG 
REACTIONS IN NURSING HOMES 
3.1 ABSTRACT 
3.1.1 OBJECTIVES 
To develop a consensus list of agreed upon laboratory, pharmacy, and Minimum Data Set signals 
that can be used by a computer system in the nursing home to detect potential adverse drug 
reactions (ADRs). 
3.1.2 DESIGN AND SETTING 
Literature search for potential ADR signals, followed by an Internet-based, two-round, modified 
Delphi survey of experts in geriatrics. 
3.1.3 PARTICIPANTS 
Panel of 13 physicians, 10 pharmacists, and 13 advanced practitioners. 
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3.1.4 MEASUREMENTS 
Mean score and 95% confidence interval (CI) for each of 80 signals rated on a 5-point Likert 
scale (5=strong agreement with likelihood of indicating potential ADRs). Consensus agreement 
indicated by a lower-limit 95% CI of ≥4.0. 
3.1.5 RESULTS 
Panelists reached consensus agreement on 40 signals: 15 laboratory/medication combinations, 12 
medication concentrations, 10 antidotes, and 3 Resident Assessment Protocols (RAPs).  Highest 
consensus scores (4.6; 95% CI, 4.4–4.9 or 4.4–4.8) were for naloxone when taking opioid 
analgesics; phytonadione when taking warfarin; dextrose, glucagon, or liquid glucose when 
taking hypoglycemic agents; medication-induced hypoglycemia; supratherapeutic international 
normalized ratio when taking warfarin; and triggering the Falls RAP when taking certain 
medications. 
3.1.6 CONCLUSION 
A multidisciplinary expert panel was able to reach consensus agreement on a list of signals to 
detect potential ADRs in nursing home residents.  The results of this study can be used to 
prioritize an initial list of signals to be included in paper or computer-based methods for potential 
ADR detection. 
  33 
3.2 INTRODUCTION 
Adverse drug reactions (ADRs) are the most frequent medication-related adverse events in the 
nursing home setting, with an incidence ranging from 1.19 to 7.26 per 100 resident-months.7  
Other types of medication-related adverse events, include therapeutic failures and adverse drug 
withdrawal events.  However, their precise incidence and impact have not been well 
characterized in the literature.139  Data from the largest study on adverse drug reactions (ADRs) 
in nursing homes suggest that over half of the events are preventable, and that 70% are 
associated with monitoring errors.10  Although comprehensive chart review is the primary ADR 
case-finding technique for research, and is considered by some to be the "gold standard,"30 it is 
time-consuming, costly, and impractical for routine clinical use.29  Therefore, alternative 
surveillance systems are needed in nursing homes to detect and minimize the potential 
consequences of ADRs. 
ADRs can be detected by computerized clinical event monitors via the processing of 
laboratory test result signals and pharmacy order signals.31, 55-56  Hospital studies indicate that 
these automated clinical decision-support systems, which provide feedback to healthcare 
professionals based on information available in electronic format, are less expensive and much 
faster to use than manual chart reviews, and can identify events not normally detected by 
clinicians during the course of routine care.30, 57  More recently, computerized ADR detection has 
been examined in the ambulatory and nursing home settings using many of the same pharmacy 
and laboratory signals used by hospital-based systems.11, 31, 140 
ADR signals from pharmacy order and laboratory test results in nursing homes are likely 
to differ from those used in the hospital setting.  This is because the number and types of 
medications prescribed and the laboratory tests ordered for nursing home residents vary 
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considerably from those of hospitalized patients.141  With the trend towards centralization of 
laboratory, pharmacy, and Minimum Data Set data, resident-specific information available in 
electronic format is becoming increasingly more available in nursing homes.142  The purpose of 
this study was to develop a consensus list of laboratory, pharmacy, and Minimum Data Set 
signals that can be used by a computer system in the nursing home to detect potential ADRs. 
3.3 METHODS 
3.3.1 Literature Review and Identification of Initial Set of Signals 
We conducted a comprehensive literature search to create a preliminary list of signals that can be 
used to detect potential ADRs in nursing homes. With the assistance of a medical librarian, we 
searched OVID MEDLINE, OVID CINHAL, and EMBASE for articles published in all 
languages between January 1, 1985, and July 1, 2006.  In OVID, we searched for the following 
medical subject headings (MeSH) keywords, and text words: aged, adverse drug event, adverse 
drug reaction, adverse drug reaction reporting systems, clinical event monitor, clinical decisions 
support systems, clinical laboratory information systems, clinical pharmacy information system, 
computer generated signals, decision support system, drug monitoring, homes for the aged, 
medication errors, nursing homes, and physiologic monitoring.  In EMBASE, we searched for 
the above terms, plus the following EMTREE keywords: computer assisted drug therapy and 
drug surveillance program.  The first author (SMH) supplemented the computerized search by 
reviewing the reference lists from the identified articles, recent reviews, textbooks, and personal 
files. 
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A total of 29 publications were identified.6-8,10-35  Two authors (SMH and JTH) reviewed 
these publications for relevance, compiled a preliminary list of signals, and placed each potential 
signal into one of four categories: 1) laboratory/medication combination signals (triggered by 
abnormal laboratory values when certain medications are present); 2) medication concentration 
signals (triggered by elevated, or supratherapeutic medication concentrations); 3) antidote signals 
(triggered by administration of medications given to counteract the effects of a medication with 
toxic effects); 4) Resident Assessment Protocol (RAP)143 signals (triggered by responses to 
certain Minimum Data Set items, and taking of certain medications).  The first author (SMH) 
used standard pharmacology textbooks144-146 to provide specific examples of medications that 
may be associated with the firing of each of the signals (e.g., elevated creatinine caused by 
diuretics or hyperglycemia caused by prednisone) with the goal of clarifying the signals.  Then 
other members of the clinical investigative team (JTH, DAN, DBF, and SAS) reviewed and 
further refined the list of signals. 
The final list consisted of 35 laboratory/medication combination signals, 16 medication 
concentration signals, 20 antidote signals, and 9 RAP signals, for a total of 80 signals (Appendix 
A) to be included in the Delphi survey. 
3.3.2 Selection of Study Methodology and Participants 
Our study involved the use of an Internet-based, two-round, modified Delphi survey of experts in 
the field of nursing home care.  The Delphi methodology is a structured group interaction 
process that is directed in "rounds" of opinion collection and feedback.147  We selected the 
modified web-based Delphi consensus method because research suggests that accurate and 
reliable assessments can be achieved by consulting a panel of experts and subsequently accepting 
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the group consensus as the best estimate of the answer to a particular question.148  The modified 
Delphi method is especially useful in studies that deal with medication safety in older adults.149-
152  The methodology used in this study differed from the Delphi process developed by the 
RAND Corporation that relies on face-to-face meetings to achieve consensus.153  However, the 
modified method enables a group of experts to be contacted inexpensively and without 
geographic limitations.  The rounds of the survey were completed confidentially, allowing each 
participant to present and react to ideas without being biased by knowing the identities of other 
participants. 
We selected a multidisciplinary expert panel of members from three professions: 
physicians, pharmacists, and advanced practitioners (i.e., physician assistants or nurse 
practitioners).  We chose these professions because they are all involved in the monitoring phase 
of the medication use process (i.e., assess resident response to medication and document 
outcomes).154  After obtaining the names of potential participants from national geriatrics or 
nursing home organizations, we selected individuals based on their extensive clinical practice or 
large number of publications in the area of nursing home care.  Our goal was to have a similar 
number of participants from each profession.  Because we had encountered a low response rate 
from some groups in a previous study,50 we invited a total of 57 health care professionals, 
including 23 physicians, 13 pharmacists, and 21 advanced practitioners to participate. 
To improve the response rate and reduce the possibility of nonrespondent bias, we 
employed multiple methods, including university sponsorship, nominal monetary incentives ($75 
upon completion of both rounds), and having respondents complete the rounds on the Internet.155 
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3.3.3 Administration and Analysis of the Survey 
We contacted the experts through an e-mail invitation included with round 1.  We asked them to 
complete each survey round within 2 weeks, and sent them a reminder e-mail if they did not do 
so.  During each round, we provided participants with a list of signals, a list of medications that 
might be associated with the firing of each signal, and supporting references concerning the 
signals.  We asked them to use a 5-point Likert scale to evaluate their agreement or disagreement 
with statements concerning the likelihood that each signal would be associated with a potential 
ADR in the nursing home setting.  The scale ranged from 1, (indicating strong disagreement), to 
5, (indicating strong agreement).  For the purposes of the study, we operationally defined a 
nursing home as having custodial, skilled, and subacute levels of care. At the completion of 
round 1, we gave the participants the opportunity to modify existing signals or provide 
suggestions for additional signals to include in round 2. We determined in advance that we 
would include any new or modified signals that were suggested by 2 or more participants. 
After round 1, we compiled the scores and computed a weighted mean score and 95% 
confidence interval (CI) for each signal.  The weighting of individual ratings was designed to 
ensure that all three professions had equal influence, regardless of the number of participants in 
each profession.  Based on work previously published by our group,156-158 we examined the 
lower and upper limits of the 95% CIs, and then classified each signal into one of three 
categories: accepted signals, defined as those having a score with a lower-limit 95% CI of ≥4.0 
(indicating consensus agreement); rejected signals, defined as those having a score with an 
upper-limit 95% CI of <3.0 (consensus disagreement); or equivocal, defined as those having a 
score with a lower-limit 95% CI between 3.0 and 3.9 (indicating the need for reevaluation). 
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In round 2, we did not include the signals that were already accepted or already rejected.  
We included only the equivocal signals from round 1.  For each equivocal signal, we provided 
each participant with his or her round 1 individual score and with the round 1 weighted mean 
group score to aid in the consensus-building process. 
After round 2, we repeated the processes of compiling scores and computing weighted 
scores and 95% CIs.  Again, the weighting of individual ratings ensured that all three professions 
had equal influence.  We again classified signals as accepted if they had a lower-limit 95% CI of 
≥4.0 (indicating consensus agreement). We classified all other signals as rejected.  
For all statistical analyses, we used SAS version 9 for Windows (SAS Institute, Inc., 
Cary, NC).  The University of Pittsburgh Institutional Review Board approved the study as 
exempt; hence, informed consent was not needed for study participation.  The external funding 
sources had no involvement in study design or collection, analysis, or interpretation of data, nor 
did they review or approve this manuscript. 
3.4 RESULTS 
3.4.1 Round 1 
For round 1, the study included 13 physicians, 10 pharmacists, and 13 advanced practitioners, for 
an overall response rate of 63.2% (36/57).  The response rate was 56.5% (13/23) for the invited 
physicians, 61.9% (13/21) for the invited advanced practitioners, and 76.9% (10/13) for the 
invited pharmacists.  The majority of participants were female (66.7%), were affiliated with an 
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academic medical center (63.9%), and worked in the nursing home setting for a median of 5 
years (100%).  
At the end of round 1, of the 80 signals that were considered, 32 were accepted, 0 were 
rejected, and 48 were equivocal.  The accepted signals were 13 laboratory/medication 
combination signals (Table 5), 6 medication concentration signals (Table 6), 10 antidote signals 
(Table 7), and 3 RAP signals (Table 8). There were no signals suggested by two or more 
panelists. 
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Table 5. Final Consensus List of Laboratory/Medication Combination Signals for Detecting Adverse 
Drug Reactions in the Nursing Home Setting. 
Laboratory/Medication Combination Signals* Mean Score 
95% 
CI 
Hypoglycemia (as indicated by a low or decreasing glucose 
concentration) is found in an individual taking a drug that may 
cause or worsen hypoglycemia 
 
4.6 
 
4.4–4.8 
Supratherapeutic (above upper limit of normal range) international 
normalized ratio (INR) is found in an individual taking warfarin 
4.6 4.4–4.8 
Clostridium difficile toxin is found in an individual taking a drug that 
may cause pseudomembranous colitis 
4.5 4.3–4.7 
Hyperkalemia (as indicated by a high or increasing potassium 
concentration) is found in an individual taking a drug that may 
cause or worsen hyperkalemia 
4.5 4.3–4.7 
Hypokalemia (as indicated by a low or decreasing potassium 
concentration) is found in an individual taking a drug that may 
cause or worsen hypokalemia 
4.5 4.3–4.7 
Thrombocytopenia (as indicated by a low or decreasing platelet 
count) is found in an individual taking a drug that may cause or 
worsen thrombocytopenia 
4.5 4.3–4.7 
Supratherapeutic activated partial thromboplastin time (PTT) is found 
in an individual taking heparin 
4.4 4.2–4.7 
Subtherapeutic concentration (below lower limit of normal range) of 4.4 4.2–4.6 
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thyroid-stimulating hormone (TSH) or elevated concentration of 
thyroxine (T4) is found in an individual taking a drug that may 
cause hyperthyroidism 
Hyponatremia (as indicated by a low or decreasing sodium 
concentration) is found in an individual taking a drug that may 
cause or worsen hyponatremia 
4.4 4.2–4.5 
Leukopenia (as indicated by a low or decreasing white blood cell 
count) is found in an individual taking a drug that may cause or 
worsen leukopenia 
4.3 4.1–4.6 
Elevated alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) concentration is found in an individual 
taking a drug that may cause hepatocellular toxicity 
4.3 4.1–4.5 
Elevated creatinine or blood urea nitrogen (BUN) concentration is 
found in an individual taking a drug that may increase creatinine or 
BUN 
4.3 4.1–4.5 
Supratherapeutic concentration of TSH or decreased concentration of 
T4 is found in an individual taking a drug that may cause 
hypothyroidism† 
4.3 4.1–4.4 
Agranulocytosis or neutropenia (as indicated by a low or decreasing 
neutrophil count) is found in an individual taking a drug that may 
cause or worsen agranulocytosis or neutropenia† 
4.2 4.1–4.3 
Elevated creatine phosphokinase (CPK) concentration is found in an 
individual taking a drug that may increase CPK 
4.2 4.0–4.4 
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*Panel members rated each item on a 5-point Likert scale, with 5 indicating strong agreement 
with the likelihood that the item signaled an adverse drug reaction. The mean likelihood score 
and 95% confidence interval (CI) were calculated for each item. Panel consensus was 
indicated by a lower-limit 95% CI of ≥4.0.  
†Panel consensus was not reached until round 2 of the Delphi survey. 
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Table 6. Final Consensus List of Medication Concentration Signals for Detecting Adverse Drug 
Reactions in the Nursing Home Setting. 
Medication Concentration Signals* Mean Score 
95% 
CI 
Aminoglycoside peak or trough concentration is supratherapeutic in an 
individual taking an aminoglycoside antibiotic (e.g., amikacin, 
gentamicin, or tobramycin) 
4.4 4.2–
4.7 
Phenytoin concentration is supratherapeutic in an individual taking 
phenytoin 
4.4 4.1–
4.7 
Lithium concentration is supratherapeutic in an individual taking 
lithium† 
4.3 4.1–
4.5 
Theophylline trough concentration is supratherapeutic in an individual 
taking theophylline 
4.3 4.0–
4.7 
Digoxin concentration is supratherapeutic in an individual taking digoxin 4.3 4.0–
4.6 
Procainamide concentration or N-acetylprocainamide 
(NAPA)concentration is supratherapeutic in an individual taking 
procainamide 
4.3 4.0–
4.6 
Primidone (Mysoline) concentration or phenobarbital concentration is 
supratherapeutic in an individual taking primidone 
4.3 4.0–
4.5 
Quinidine concentration is supratherapeutic in an individual taking 
quinidine† 
4.2 4.1–
4.4 
Valproic acid concentration is supratherapeutic in an individual taking 4.2 4.1–
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valproic acid† 4.4 
Phenobarbital concentration is supratherapeutic in an individual taking 
phenobarbital† 
4.2 4.0–
4.5 
Carbamazepine concentration is supratherapeutic in an individual taking 
carbamazepine† 
4.2 4.0–
4.4 
Disopyramide (Norpace) concentration is supratherapeutic in an 
individual taking disopyramide† 
4.2 4.0–
4.4 
*Panel members rated each item on a 5-point Likert scale, with 5 indicating strong agreement with 
the likelihood that the item signaled an adverse drug reaction. The mean likelihood score and 
95% confidence interval (CI) were calculated for each item. Panel consensus was indicated by a 
lower-limit 95% CI of ≥4.0.  
†Panel consensus was not reached until round 2 of the Delphi survey. 
 
  45 
Table 7. Final Consensus List of Antidote Signals for Detecting Adverse Drug Reactions in the 
Nursing Home Setting. 
Antidote Signals* 
Mean 
Score 
 
95% CI 
Naloxone (Narcan) is given to an individual taking an opioid analgesic 4.6 4.4–4.9 
Phytonadione (vitamin K) in oral, subcutaneous, or intravenous form is 
given to an individual taking warfarin 
4.6 4.4–4.9 
Dextrose 50%, glucagon, or liquid glucose is given to an individual 
taking a drug that may cause hypoglycemia 
4.6 4.4–4.8 
Protamine sulfate is given to an individual taking heparin 4.5 4.3–4.8 
Digoxin immune Fab (Digibind) is given to an individual with a 
supratherapeutic digoxin concentration 
4.5 4.2–4.8 
Epinephrine is given to an individual taking a drug that may cause an 
anaphylactic reaction 
4.4 4.1–4.8 
Metronidazole (oral) or vancomycin (oral) is given to an individual who 
has recently taken a drug that may cause pseudomembranous colitis 
4.4 4.1–4.7 
Benztropine (Cogentin), diphenhydramine, or trihexyphenidyl (Artane) is 
given to an individual taking a drug that may cause extrapyramidal 
symptoms 
4.4 4.1–4.6 
Lepirudin (Refludan) is given to an individual taking a drug that may 
cause heparin-induced thrombocytopenia 
4.4 4.1–4.6 
Sodium polystyrene (Kayexalate) is given to an individual taking a drug 
that may cause hyperkalemia 
4.3 4.0–4.6 
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*Panel members rated each item on a 5-point Likert scale, with 5 indicating strong agreement with 
the likelihood that the item signaled an adverse drug reaction. The mean likelihood score and 
95% confidence interval (CI) were calculated for each item. Panel consensus was indicated by a 
lower-limit 95% CI of ≥4.0. For all items shown, panel consensus was reached during round 1 
of the Delphi survey. 
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Table 8. Final Consensus List of Resident Assessment Protocol (RAP) Signals for Detecting Adverse 
Drug Reactions in the Nursing Home Setting. 
RAP Signals* 
Mean 
Score 
 
95% CI 
Falls RAP is triggered in an individual taking a drug that may cause or 
worsen falls (falls with or without injury) 
4.6 4.4–4.8 
Delirium RAP is triggered in an individual taking a drug that may cause 
or worsen delirium (periodic disordered thinking or awareness) 
4.5 4.3–4.7 
Dehydration/Fluid Maintenance RAP is triggered in an individual taking 
a drug that may cause or worsen dehydration (fluid loss exceeding the 
amount of fluid intake)  
4.4 4.2–4.6 
*Panel members rated each item on a 5-point Likert scale, with 5 indicating strong agreement with 
the likelihood that the item signaled an adverse drug reaction. The mean likelihood score and 
95% confidence interval (CI) were calculated for each item. Panel consensus was indicated by a 
lower-limit 95% CI of ≥4.0. For all items shown, panel consensus was reached during round 1 
of the Delphi survey. 
3.4.2 Round 2 
For round 2, the study included 11 of the 13 physicians, all 10 of the pharmacists, and all 13 of 
the advanced practitioners.  The overall response rate for round 2 was 94.4% (34/36). At the end 
of round 2, of the 48 signals that were reconsidered because of their earlier equivocal 
classification, 8 were accepted.  The accepted signals were 2 laboratory/medication combination 
signals (Table 5) and 6 medication concentration signals (Table 6). 
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Overall, 15 of 35 (42.9%) of the laboratory/medication combination signals, 12 of 16 
(75%) of the medication concentration signals, 10 of 20 (50%) of the antidote signals, and 3 of 9 
(33.3%) of the RAP signals reached consensus and were accepted. 
The highest consensus scores (4.6; 95% CI, 4.4–4.9 or 4.4–4.8) were for naloxone when 
taking opioid analgesics; phytonadione (Vitamin K) when taking warfarin; dextrose, glucagon, 
or liquid glucose when taking hypoglycemic agents; medication-induced hypoglycemia; 
supratherapeutic international normalized ratio when taking warfarin; and triggering the Falls 
RAP when taking certain medications. 
3.5 DISCUSSION 
A multidisciplinary expert panel of nursing home physicians, pharmacists, and advanced 
practitioners were able to reach consensus agreement on a list of 40 signals that can be used by a 
computer system to detect potential ADRs in the nursing home setting.  Laboratory/medication 
combinations accounted for over one-third of all signals that reached consensus.  Of the 15 
laboratory/medication combination signals that the panelists agreed were appropriate for the 
nursing home setting, 8 were not reported in the 2005 study of Gurwitz et al.,11 which to our 
knowledge is the only published study concerning a clinical event monitor to detect potential 
ADRs in nursing homes.  These 8 additional signals were drug-induced episodes of the 
following: hypoglycemia, hyponatremia, leukopenia, agranulocytosis/neutropenia, a 
supratherapeutic activated partial thromboplastin time, a supratherapeutic thyroid stimulating 
hormone concentration, an elevated creatinine or blood urea nitrogen concentration, and an 
elevated creatine phosphokinase concentration. 
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The next most common signal category reaching consensus was medication 
concentrations.  The goal of therapeutic medication monitoring is to guide dosing by means of 
drug concentration measurements.  This is particularly useful in cases in which the range 
between the dose necessary to achieve beneficial effects and the dose causing ADRs is narrow, 
and when the medication concentration is not readily predictable from the dose prescribed.  
Moreover, serum medication concentrations are likely to be most useful when used to help 
confirm or refute a resident’s signs or symptoms suggestive of toxicity or lack of efficacy.  When 
the panelists were asked to consider 16 medication concentration signals, they achieved 
consensus on 12 (75%), and it is not surprising that these were for drugs with narrow therapeutic 
ranges.  
A recent study by Raebel et al.,25 suggests that monitoring narrow therapeutic range 
drugs is not being done routinely, with as many as 50% of older adults not receiving drug 
concentration monitoring during 1 year of use.  To reduce the potential for ADRs in the nursing 
home setting, the Center for Medicare and Medicaid Services (CMS) recommends routine 
periodic medication monitoring for most narrow therapeutic range drugs listed in their F329  
guidelines (the deficiency citation for unnecessary drugs).159  This CMS recommendation 
extends to all residents, regardless of whether they are exhibiting signs or symptoms suggestive 
of toxicity or lack of efficacy.  It is important to note however that if a medication concentration 
comes back elevated when ordered for diagnostic purposes, the likelihood of a potential ADR is 
significantly higher then if it was being ordered on a routine basis.  The rationale for this is that 
the prior odds of a potential ADR are significantly increased because the underlying assumption 
is that the resident is already receiving the medication of interest, and the prescribing clinician is 
aware of the possibility of an ADR.113  Of note, our panelists reached consensus on 3 narrow 
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therapeutic range drugs not mentioned in the F329 guidelines—namely, concentrations of Class 
Ia antiarrhythmics including: procainamide, disopyramide, and quinidine. 
Antidote signals accounted for one-quarter of the final 40 signals.  Four of the 10 antidote 
signals had not been reported in the study of Gurwitz et al.,11 and these were the administration 
of epinephrine, digoxin immune Fab, lepirudin, or a medication with anticholinergic properties 
to treat extrapyramidal symptoms.  Four of the 10 antidote signals that had been reported by 
Gurwitz et al.11 did not reach consensus in our study, and these were the administration of an 
antihistamine, an oral or topical steroid, or topical nystatin and the administration of a 
hypoglycemic agent to an individual taking glucocorticoids.  It is important to note, that in a 
recent systematic review of the signals used by hospital-based clinical event monitors to detect 
potential ADRs, the antidote signal category had the lowest overall positive predictive values.60  
The authors of this review concluded that the performance characteristics of this signal category 
was lowest because antidotes can be used to treat multiple medical conditions, only a fraction of 
which are related to the presence of an ADR. 
Unique to this study was that consensus was reached on 3 RAP signals.  Studies in the 
nursing home setting are currently evaluating the effectiveness of computerized decision support 
systems on 2 of the RAP signals on which our panelists reached consensus—namely, the Falls 
RAP and the Delirium RAP.160  This reflects that the evidence for certain medications being 
associated with these specific geriatric syndromes is generally well accepted.161-162  Participants 
also reached consensus that the Dehydration/Fluid Maintenance RAP be used as a signal to 
detect potential ADRs for individuals taking certain medications. 
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3.5.1 Strengths and Limitations 
Our study had several strengths.  First, we chose to include a multidisciplinary panel of 
physician, pharmacist, and advanced practitioner experts to determine which signals can be used 
to detect potential ADRs.  Our methodology ensured that all clinicians involved in the 
monitoring phase of the medication use process in the nursing home setting were included, and 
that their responses were weighted to ensure that each profession had an equal influence on the 
results.  Second, to improve the survey response rate and reduce the possibility of nonrespondent 
bias, we employed multiple methods, including university sponsorship, monetary incentives, 
providing the survey on the Internet, and the distributing reminders to participants.155  The 
overall initial and second round response rates in our study exceeded the minimally acceptable 
mean response rate of 60% for mail surveys reported in the medical literature.163 
Our study had several potential limitations.  First, we used a convenience sample of 
physician, pharmacist, and advanced practitioner experts to participate in the Delphi survey.  As 
a result, the majority of respondents were affiliated with an academic institution.  Using a 
random sampling technique may have strengthened the study by increasing the generalizability 
to the universe of clinical practitioners.  Second, we did not hold face-to-face meetings of the 
panelists, a practice that is sometimes done with Delphi surveys.148, 153, 164  Bringing the panelists 
together allows individual respondents to incorporate the perspectives of others, and may have 
resulted in further refinement of the signals while facilitating the consensus process.  However, 
in person meetings might have limited the broad geographic representation we were able to 
achieve with the use of the Internet.  In addition, by offering two rounds in the survey, 
respondents did benefit from seeing the opinions of others.  Third, we did not provide 95% 
confidence intervals for equivocal signals to panelists during the second round.  Information on 
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the distribution of responses may have been useful to the panelists in order to achieve consensus.  
Fourth, the panelists reached consensus on 40 signals at this time. As new research contributes 
more information about medication safety, the list of signals will need to be modified and may 
expand. 
3.5.2 Implications and Further Research 
The Institute of Medicine recommends that all health care facilities continuously assess 
medication safety through the development and evaluation of various types of data-driven 
triggers for detecting ADRs.  This assessment should occur during routine monitoring, and for 
diagnostic confirmation of signs or symptoms suggestive of toxicity or lack of efficacy.23, 41  
Clinical event monitors can address this recommendation by integrating various sources of 
information for the purpose of ADR detection. All nursing homes are currently capable of 
transmitting Minimum Data Set information electronically, and the use of computerized 
laboratory and medication records is likely to increase significantly over the coming years.73  
These monitors are feasible given knowledge of the data structure of the information resources 
and certain programming capacity.  In nursing homes with appropriate health information 
technology infrastructure, the results of our study can be used to create or modify clinical event 
monitor systems to automate the detection of potential ADRs.  
In nursing homes without appropriate infrastructure, the results can be used to prioritize 
the signals to be included in a paper-based trigger tool.  The trigger tool methodology, developed 
in part by the Institute of Healthcare Improvement, greatly simplifies the chart review process by 
allowing rapid and systematic examination of charts to extract relevant data.  Trigger tools have 
been successfully used to demonstrate the benefits of low-cost error detection strategies focused 
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on high-risk medications in a variety of clinical settings.165-166  Regardless of whether computer 
or paper-based methods for detecting potential ADRs are used, a more detailed assessment of the 
resident would be required to determine if an actual ADR is present. 
Further research is needed in several areas.  Formal research is needed to determine the 
incidence and the positive predictive values of individual signals in nursing homes with different 
levels of care (e.g., custodial, skilled, and subacute care).  Future studies are also needed to 
improve the performance characteristics of antidote signals, which can possibly be enhanced by 
linking the use of these medications to changes in drug therapy or interventions that occurred 
prior to their use.  These data will help nursing homes further prioritize the signals to be included 
in their computerized or paper-based trigger tools, and will thereby help them maximize the 
detection of potential ADRs, and minimize the number of false-positive alerts.  Studies should 
also be conducted to determine if certain errors of omission, including the failure to monitor 
narrow therapeutic index medications or conduct laboratory studies while prescribing certain 
medications, may lead to an increase in potential ADRs in the nursing home setting.  Research is 
also needed to determine if ADR detection rates can be improved by combining multiple data 
sources (e.g., laboratory, pharmacy, and health care records) to gain a better understanding of the 
context of the data as they relate to residents' underlying medical conditions.130-131, 167 
3.6 CONCLUSION 
A multidisciplinary expert panel was able to reach consensus agreement on a defined list of 
signals of potential ADRs in nursing home residents.  This is a necessary initial step toward 
detecting and reducing the future occurrence and impact of ADRs in the nursing home setting.  
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The results of this study can be used to prioritize an initial list of signals to be included in paper 
or computer-based method for potential ADR detection. 
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4.0  ASSESSING THE PERFORMANCE CHARACTERISTICS OF SIGNALS USED 
BY A CLINICAL EVENT MONITOR TO DETECT ADVERSE DRUG REACTIONS IN 
THE NURSING HOME 
4.1 ABSTRACT 
4.1.1 Objective 
Adverse drug reactions (ADRs) are a common cause of morbidity and mortality in the nursing 
home (NH) setting.  Traditional non-automated mechanisms for ADR detection are time-
consuming, costly, and fail to detect the majority of ADRs.  The objective of this study was to 
determine the incidence and positive predictive values of signals specifically designed for use by 
a clinical event monitor to detect ADRs in the NH setting. 
4.1.2 Design 
Case-series. 
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4.1.3 Measurement/Methods 
All patients, except those enrolled in hospice, were included in the 15-week study period 
(October 1, 2007 to January 13, 2008) and who had one of 37 signals present were evaluated.  
Alerts were assessed using the Naranjo causality algorithm.  Positive predictive values (PPVs) 
were calculated as the proportion of alerts that occurred, divided by the number of times that 
alerts occurred and ADRs were confirmed.  
4.1.4 Results 
The overall PPV for all signals combined was 81% (54/67), with individual signal PPVs ranging 
from 0-100%. The PPVs were 53% (10/19) for the antidote signals category and 96% (44/46) for 
the laboratory/ medication combination signals category. The majority 75% (12/16) of the 
preventable ADRs were laboratory/medication combination signals. 
4.1.5 Conclusion 
The results suggest that ADRs can be detected in the NH setting with a high degree of accuracy 
using a clinical event monitor that employs a set of signals derived by expert consensus. 
4.2 INTRODUCTION 
The most frequent medication-related adverse events in nursing homes in the United States are 
adverse drug reactions (ADRs).7  ADRs are defined by the World Health Organization as 
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unintended or noxious responses to a drug given in a dosage intended for prophylaxis, diagnosis, 
or therapy.5  In the nursing home (NH) setting, the incidence of ADRs ranges from 1.19 to 7.26 
per 100 patient-months.  Although comprehensive chart review is the primary ADR case-finding 
technique for research, and is considered by some to be the "gold standard," it is time-
consuming, costly, and impractical for routine clinical use.30  Therefore, a critical need exists for 
the development of alternative strategies to detect ADRs in NHs. 
ADRs can be detected by computerized clinical event monitors through the processing of 
pharmacy order signals and laboratory test result signals.  Hospital studies indicate that these 
automated clinical decision support systems, which provide feedback to healthcare professionals 
based on information available in electronic format, are less expensive and much faster to use 
than manual chart reviews, and can identify events not often detected by clinicians during the 
course of routine care.30  However, there is increasing concern about the false-positive alerts 
(i.e., alert fatigue) generated by hospital-based clinical event monitors which have been in use 
for over two decades, and have been described in more detail in a recent systematic review.60 
More recently, computerized ADR detection has been examined in the ambulatory and 
NH settings using largely the same pharmacy and laboratory signals used by hospital-based 
systems.11, 31  The objective of this study was to determine the incidence and positive predictive 
values of signals specifically designed for use by a clinical event monitor to detect ADRs in the 
NH setting. 
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4.3 METHODS 
4.3.1 Setting and Subjects  
The project was conducted in a single, independently owned, non-profit NH affiliated with the 
University of Pittsburgh Medical Center.  The facility is located in a suburban setting, with 178 
licensed beds. Prescribers were primarily community physicians and advanced practitioners (i.e., 
nurse practitioners and physician assistants).  All patients, except those enrolled in hospice, were 
included in the 15-week study period (October 1, 2007 to January 13, 2008).  The study protocol 
was reviewed and determined to be a quality improvement project by the University of 
Pittsburgh Institutional Review Board (IRB).  The University of Pittsburgh Medical Center Total 
Quality Council approved this study as a quality improvement project.  No additional IRB 
approval was required prior to publication. 
4.3.2 Source of Patient Data 
The Medical Archival System (MARS) data repository has been collecting and archiving clinical 
and financial records from all University of Pittsburgh Medical Center hospitals since 1986.168  
In order to collect relevant nursing-home specific patient data in electronic format, we developed 
a new data repository, called MARS-LTC. MARS-LTC contains long-term care (e.g., NH)  
specific patient data that are stored as they are generated. Current real-time data feeds exist for 
laboratory data (Quest Diagnostics), pharmacy data (Rx Partners-LTC), and census and 
Minimum Data Set data (Achieve Healthcare Technologies). 
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4.3.3 Clinical Event Monitor Description 
MARS-AiDE is a rule-based expert system that consists of a knowledgebase of signals that are 
applied by a rule engine to patient data contained within MARS-LTC.  An overview of the 
MARS-AiDE clinical event monitor is shown in the Figure 3 below. 
Data Repository
Pharmacy
Data Laboratory
Data
Knowledge-base of 76 
rules based on 37 
signals
Consultant Pharmacist 
Notification
Census and
Minimum Data Set Data
MARS-LTC
Quest Diagnostics
Rx Partners-LTC
Achieve Healthcare 
Technologies
MARS-AiDE
 
Figure 3. Overview of MARS-AiDE clinical event monitor for detecting adverse drug reactions. 
 
We identified all active NH patients in the census database in MARS-LTC.  Using the 
medical record number from the census, a list of active medications was generated.  For certain 
rules, this information was then compared against current laboratory information.  This process 
generated a list of alerts that fulfills the conditions of one or more of the signals, suggesting a 
potential ADR. 
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4.3.4 Signals Used by the Clinical Event Monitor 
A detailed description of the development and selection of the knowledgebase of signals to 
detect potential ADRs in the NH is reported elsewhere.78  Briefly, a multidisciplinary expert 
panel of NH physicians, pharmacists, and advanced practitioners reached consensus agreement 
on a list of 40 signals that a clinical event monitor can use to detect potential ADRs in the NH 
setting. 
In this manuscript, we present the findings associated with 37 of the 40 signals 
categorized into one of the following three groups: 1) 15 laboratory/medication combination 
signals (triggered by abnormal laboratory values when certain medications are present); 2) 12 
medication concentration signals (triggered by elevated, or supratherapeutic medication 
concentrations); and, 3) 10 antidote signals (triggered by administration of medications given to 
counteract the effects of a medication with toxic effects).  The 3 Resident Assessment Protocol 
signals (triggered by responses to certain Minimum Data Set items, and taking of certain 
medications) will be presented in a subsequent publication. 
For each of the 37 signals, we created additional rules to try and improve specificity. This 
resulted in a total of 24 laboratory/medication combination rules, 32 medication concentration 
rules, and 20 antidote rules.  For example, the elevated creatinine or blood urea nitrogen 
concentration signal was operationalized into the following 3 rules: absolute increase > 0.25 
mg/dL in baseline serum creatinine, relative increase > 25% in baseline serum creatinine, and 
absolute increase > 10 mg/dL in baseline blood urea nitrogen. 
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4.3.5 Knowledge Engineering/Development 
For each of the 15 laboratory/medication combination signals, the first author (SMH) used 
standard pharmacy reference textbooks to create an initial list of medications that were reported 
to be associated with a particular laboratory abnormality.  A drug information specialist (AHK) 
expanded the initial list of medications by using additional online references.  The drug 
information specialist then conducted a comprehensive primary literature search using OVID, 
MEDLINE, and PUBMED for articles published in the English language between January 1, 
1975, and July 1, 2007, using various MeSH terms and limiting the search to adults. 
Based on the results of the primary literature search, additional medications were added if 
the evidence supporting the association between the medication and laboratory test of interest 
was derived from case reports or study designs with stronger empirical evidence (e.g., case 
series, cohort studies, case-control, cohort studies with controls, etc.).  Similarly, medications 
were removed from the initial list if evidence was not sufficient to support the association 
between the medication and laboratory test of interest.  Any discrepancies in the data regarding 
the association between the medication and laboratory test of interest were resolved by 
discussion between two study investigators (SMH and JTH). 
4.3.6 Clinician Notification 
Similar to other clinical event monitors, the rules within MARS-AiDE are used to define 
computer-detectable events that potentially indicate an ADR.  The MARS-AiDE system is 
designed as a screening tool. Its signals and associated rules have been chosen to be sensitive, 
but not specific.  When the conditions specified by a rule are met, the MARS-AiDE system 
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issues an alert to be acted upon by a consultant pharmacist (a pharmacist who is mandated by 
United States Federal law to review and manage the medication regimens of NH patients). 
On a weekly basis during the study period, a consultant pharmacist received a list of 
patients by email that contained alerts detailing the possible ADRs during the previous 7 days.  
Each alert showed the patient’s location, medical record number, attending physician, the rule 
that was triggered, and the date and time of the firing. Each alert also included extensive 
medication information, including the name, strength, frequency, route of administration, start 
and stop date, and if the medication was a standing or an as-needed (PRN) medication.  If the 
alert was triggered by laboratory data, then each record also included the normal laboratory 
reference range, the most recent value, and the baseline value and corresponding dates (when 
available) (Figure 4). 
 
Figure 4. Sample MARS-AiDE alert. 
4.3.7 Adverse Drug Reaction Assessments 
For each potential ADR alert, the consultant pharmacist used a structured implicit review process 
according to the following criteria: whether an ADR was present, if the ADR was preventable, 
and the seriousness of the ADR. 
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We used the Naranjo causality algorithm169 to determine the likelihood of whether an ADR was 
actually due to the drug identified by the clinical event monitor, rather than the result of other 
factors.  The Naranjo algorithm is used to compute a weighted score based on answers to a short 
standardized questionnaire that correlates with causality probability (Appendix B).  Similar to 
other clinical event monitor studies, computer alert signals with a score of >1 on the Naranjo 
scale, indicating a possible ADR, were classified as a true positives.104 
ADRs were considered preventable if they were associated with a medication error.  We 
used the National Coordinating Council for Medication Error Reporting and Prevention (NCC 
MERP) definition of medication errors 170, defined as any event that may cause or lead to 
inappropriate medication use or patient harm while the medication is in the control of the health 
care professional, patient, or consumer.  Medication errors were further characterized by the 
step(s) in the medication use process where the error may have occurred, including: prescribing, 
order communication, dispensing, administering, and monitoring. ADRs were considered serious 
if they resulted in a transfer to a higher level of care (e.g., emergency department evaluation or 
hospitalization) or death. 
After an extensive training period, between-pharmacist-investigator reliability for 
identifying and classifying ADRs was assessed through independent review of the same 10 
medical records by the consultant pharmacist (SBS) and two study investigators (SMH and JTH).  
All three identified and classified the incidents the same way. To assure that the ADR 
assessments were applied consistently, a senior investigator (JTH) verified the accuracy for 
every tenth patient evaluated. 
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4.3.8 Calculation of Performance Characteristics 
For counting purposes, multiple firings on the same day, for the same patient, for the same rule 
were counted as a single alert. Specifically, multiple firings triggered by a single drug 
administration (e.g., multiple administrations of sodium polystyrene for hyperkalemia) were 
treated as a single alert.  Similarly, if multiple drugs generated multiple alerts (e.g., furosemide 
and lisinopril are being administered in the presence of increasing creatinine), they were treated 
as a single alert.  When more than one drug was associated with a single potential ADR at a 
given time, the drug-event pair with the highest Naranjo was retained and used for all 
calculations. 
To calculate a positive predictive value (PPV) for each signal, we divided the number of 
times that an alert was issued with respect to a particular rule and an ADR was confirmed (i.e., 
the number of true-positives), by the number of times the alert issued with or without an ADR 
being confirmed (i.e., the sum of true-positives and false-positives).  Simple descriptive statistics 
were used to summarize ADR preventability and seriousness. 
4.4 RESULTS 
During the 15-week study period, there were a total of 274 unique patients that met inclusion 
criteria.  The clinical event monitor processed 5,729 medication orders, generating 67 alerts, an 
average of 4.8 per week.  The overall PPV for all signals combined was 81% (54/67).  Individual 
signal PPVs ranged from 0-100% (Table 9).  The PPVs were 53% (10/19) for the antidote 
signals category and 96% (44/46) for the laboratory/medication combination signals category.  
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Alerts were generated for 50% (5/10) of the antidote signals and 73% (11/15) of the 
laboratory/medication combination signals.  There were no medication concentration signal 
firings. 
Of the true positive firings, 30% (16/54) were considered preventable ADRs. The 
majority (75% or 12/16) of the preventable ADRs were laboratory/medication combination 
signals.  Of the preventable ADRs, 88% (14/16) occurred at the monitoring and 69% (11/16) at 
the prescribing stage of the medication use process.  Overall, 6% (3/54) of the confirmed ADRs 
were considered serious, requiring emergency department evaluation, or hospitalization.  All 
ADRs that were rated as serious were also considered preventable. 
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Table 9. Positive Predictive Values (PPV) of Signals to Detect Potential Adverse Drug Reactions. 
Antidote Signals 
# of 
Alerts 
#  of 
ADRs PPV (%) 
Anticholinergic medication is given to a patient taking a 
drug that may cause extrapyramidal side effects 
3 0 0 
Dextrose 50%, glucagon, or liquid glucose is given to a 
patient taking a drug that may cause hypoglycemia 
2 1 50 
Metronidazole or vancomycin is given to a patient who 
has recently taken a drug that may cause 
pseudomembranous colitis 
10 4 40 
Sodium polystyrene is given to a patient taking a drug 
that may cause hyperkalemia 
2 1 50 
Vitamin K is given to a patient taking warfarin 4 4 100 
Laboratory/Medication Signals    
Clostridium difficile toxin positive and taking a drug 
that may cause pseudomembranous colitis 
2 2 100 
Elevated alanine aminotransferase concentration and 
taking a drug that may cause or worsen hepatocellular 
toxicity 
5 5 100 
Elevated aspartate aminotransferase concentration and 
taking a drug that may cause or worsen hepatocellular 
toxicity 
8 8 100 
Elevated blood urea nitrogen (> 10mg/dL of baseline) 4 4 100 
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and taking a drug that may increase blood urea 
nitrogen 
Elevated creatinine (> 0.25mg/dL) and taking a drug 
that may increase creatinine 
4 4 100 
Elevated creatinine (> 25% of baseline) and taking a 
drug that may increase creatinine 
4 4 100 
Hyperkalemia and taking a drug that may cause or 
worsen hyperkalemia 
2 2 100 
Hypoglycemia and taking a drug that may cause or 
worsen hypoglycemia 
2 2 100 
Hypokalemia and taking a drug that may cause or 
worsen hypokalemia 
1 1 100 
Hyponatremia and taking a drug that may cause or 
worsen hyponatremia 
6 5 83 
Leukopenia and taking a drug that may cause or worsen 
leukopenia 
2 2 100 
Supratherapeutic international normalized ratio and 
taking warfarin 
3 3 100 
Thrombocytopenia and taking a drug that may cause or 
worsen thrombocytopenia 
2 2 100 
Supratherapeutic thyroid stimulating hormone and 
taking a drug that may cause or worsen 
hypothyroidism 
1 0 0 
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4.5 DISCUSSION 
Our results suggest that ADRs can be detected using a clinical event monitor in the NH setting 
with a high degree of accuracy.  The overall PPV of 81% is substantially higher than PPVs 
previously reported in the literature, which range from 3-50%.60  It is possible that our clinical 
event monitor performed better than previously described systems because: 1) we developed a 
list of consensus signals to detect potential ADRs by experts in geriatrics, rather than using 
existing hospital-based signals; 2) we simultaneously combined multiple data sources in order to 
enhance ADR detection; and, 3) we employed a standardized knowledge engineering process for 
the laboratory/medication combination signals category. 
Similar to previous studies, signals associated with laboratory test results performed 
better than antidote signals.60  The antidote signals category may not have performed as well 
because these medications can be used to treat multiple medical conditions, only a fraction of 
which are related to the presence of an ADR.  Having a better understanding of the context of the 
data as they relate to patients’ underlying medical conditions may help to improve this signal 
category’s performance.  It is also important to note that during the course of our study, no 
signals from the medication concentration category fired.  This is not entirely surprising since 
previous research suggests that a substantial proportion of older adults do not receive appropriate 
laboratory monitoring while being prescribed chronic medications.25 
Our results suggest that about one-third of the ADRs were preventable, and that of the 
preventable ADRs, 88% were associated with errors in the monitoring stage of the medication 
use process.  This differs slightly from the only other study that used a clinical event monitor to 
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detect ADRs in the NH setting, where 42% were judged preventable and 80% occurred at the 
monitoring stage.11  
4.5.1 Implications 
Developing a clinical decision support system that has a relatively low false-positive rate is 
particularly important in order to reduce alert fatigue.  Furthermore, having a system that 
produces an average of less than 5 alerts per week could allow for the routine inclusion of ADR 
assessments as part of the monthly medication regimen review process conducted by consultant 
pharmacists on all NH patients in the United States. 
4.5.2 Future Direction 
Further research needs to be conducted to do the following: 1) determine the incidence and PPVs 
of the 3 Resident Assessment Protocol signals selected by expert consensus; 2) validate the 
findings of this study for a longer period of time in NHs with differing resident or facility 
characteristics; and, 3) describe the epidemiology and patient characteristics associated with 
ADRs detected by our clinical event monitor.  The results of this study are being used by our 
health-system to select appropriate signals to develop a clinical event monitor system that can 
maximize the detection and possible prevention of potential ADRs, while minimizing the 
number of false-positive alerts. 
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4.6 CONCLUSION 
The results suggest that ADRs can be detected in the NH setting with a high degree of accuracy 
using a clinical event monitor that employs a set of signals derived by expert consensus. 
  71 
5.0  SUMMARY OF STUDY FINDINGS 
In the first paper, we identified the importance of using PPVs in performing accurate 
assessments of individual signals used to automate the detection of ADEs in the hospital setting.  
Based on this experience, we were also able to hypothesize why the performance characteristics 
were generally poor, and think of simple solutions for potentially improving them.  Finally, we 
recognized that the signals used in hospital-based active medication monitoring systems are 
likely to be different from those used in other clinical environments such as the NH setting.  
Consequently, a new set of setting-specific signals were needed. 
In the second paper, we used the list of signals in the hospital setting as a starting point, 
but then conducted a comprehensive literature search to create a preliminary list of signals that 
can be used to detect potential ADRs in nursing homes.  We then queried a panel of experts in 
geriatrics to complete an Internet-based, two-round, modified Delphi survey to develop a 
consensus list of  laboratory, pharmacy, and Minimum Data Set signals that an active medication 
monitoring system can use to detect potential ADRs in the NH setting.  Panelists reached 
consensus agreement on 40 signals, including several signals that have never been used in any 
previous system to detect ADRs. 
In the third paper, we described the implementation and pharmacist evaluation of a 
clinical event monitor using signals previously developed by a panel of experts in geriatrics.  The 
results suggest that ADRs can be detected in the NH setting with a high degree of accuracy using 
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a clinical event monitor that employs a set of signals derived by expert consensus.  The overall 
positive predictive value for all signals combined was 81%, representing the highest overall 
value ever reported in the literature. 
5.1 SIGNIFICANCE OF STUDY FINDINGS 
ADEs among NH patients are common and costly problems that are likely to increase 
substantially due to the aging U.S. population, and the increasing need for NH services.  A lack 
of easily identifiable patient-specific risk factors makes it difficult to routinely detect these 
events.  Systems analyses of ADEs suggest that suboptimal medication monitoring is the most 
common factor underlying these events in the NH.  Current strategies that rely on voluntary 
reporting, such as incident reports, direct observation of medication passes, and retrospective 
chart review are time-consuming, costly, and impractical for routine clinical use.  Several 
prominent quality improvement organizations recommend active medication monitoring systems 
as a potential solution to improving medication safety.  Active medication monitoring systems 
are particularly needed to detect ADEs in priority populations such as institutionalized elderly 
because of the long-standing concern about the quality of their pharmaceutical care.  The 
compilation of the three projects presented in this dissertation are the initial steps and first 
reported accounts of the development and testing of an active medication monitoring system for 
use in the NH setting. 
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5.2 FUTURE RESEARCH DIRECTION AND IMPLICATIONS 
Preliminary data collected by our group demonstrates that ADRs can be detected in the NH 
setting with a high degree of accuracy using an active medication monitoring system that 
employs a set of signals derived by expert consensus.  However, research conducted using a 
more rigorous study design, over a longer duration of time, and in a larger number of NHs is 
necessary before recommendations can be made about how the results of our study may affect 
clinical practice or have policy implications.  From a clinical perspective, if the active 
medication monitoring system is shown to be effective, it can help physicians detect and respond 
to ADEs more frequently and quickly when compared to usual care.  More widespread 
implementation of the system has great potential to reduce impairment of functional and 
cognitive status, morbidity, mortality, and health services utilization for institutionalized elderly.  
From a policy perspective, if shown to result in cost-savings, our results can be used to inform 
CMS and other large healthcare systems (e.g., the VA) to institute pharmacy regulations in the 
U.S. that promote the more widespread use of such active medication monitoring systems. 
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APPENDIX A 
INITIAL LIST OF 80 POTENTIAL SIGNALS FOR ADVERSE DRUG REACTIONS IN 
THE NURSING HOME SETTING, BASED ON A COMPREHENSIVE LITERATURE 
SEARCH AND CLINICAL INVESTIGATIVE REVIEW 
Medication/Laboratory Combinations 
Agranulocytosis or neutropenia (as indicated by a low or decreasing neutrophil count) is found 
in an individual taking a drug that may cause or worsen agranulocytosis or neutropenia (e.g., 
ticlopidine) 
Anemia (as indicated by a low or decreasing hemoglobin or hematocrit concentration) is found 
in an individual taking a drug that may cause or worsen anemia (e.g., nonsteroidal anti-
inflammatory agents) 
Clostridium difficile toxin is found in an individual taking a drug that may cause 
pseudomembranous colitis (e.g., fluoroquinolone antibiotics) 
Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) concentration is 
found in an individual taking a drug that may cause hepatocellular toxicity (e.g., 
thiazolidinediones) 
Elevated creatine phosphokinase (CPK) concentration is found in an individual taking a drug 
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that may increase CPK (e.g., statins) 
Elevated creatinine or blood urea nitrogen (BUN) concentration is found in an individual taking 
a drug that may increase the creatinine or BUN concentration (e.g., diuretics) 
Eosinophilia (as indicated by a high or increasing eosinophil count) is found in an individual 
taking a drug that may cause or worsen eosinophilia (e.g., proton pump inhibitors) 
Erythrocytosis (as indicated by a high or increasing hemoglobin or hematocrit concentration) is 
found in an individual taking a drug that may cause or worsen erythrocytosis (e.g., epoetin 
alpha) 
Hyperammonemia (as indicated by a high or increasing ammonia concentration) is found in an 
individual taking a drug that may cause or worsen hyperammonemia (e.g., valproic acid) 
Hyperamylasemia (as indicated by a high or increasing amylase concentration) is found in an 
individual taking a drug that may cause or worsen hyperamylasemia (e.g., nonsteroidal anti-
inflammatory agents) 
Hyperbilirubinemia (as indicated by a high or increasing bilirubin concentration), elevated 
alkaline phosphatase (ALP) concentration, or elevated gamma-glutamyltransferase (GGT) 
concentration is found in an individual taking a drug that may cause cholestatic 
hepatotoxicity (e.g., allopurinol) 
Hypercalcemia (as indicated by a high or increasing calcium concentration) is found in an 
individual taking a drug that may cause or worsen hypercalcemia (e.g., calcium 
supplements) 
Hyperchloremia (as indicated by a high or increasing chloride concentration) is found in an 
individual taking a drug that may cause or worsen hyperchloremia (e.g., laxatives) 
Hyperglycemia (as indicated by a high or increasing glucose concentration) is found in an 
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individual taking a drug that may cause or worsen hyperglycemia (e.g., prednisone) 
Hyperkalemia (as indicated by a high or increasing potassium concentration) is found in an 
individual taking a drug that may cause or worsen hyperkalemia (e.g., potassium sparing 
diuretics) 
Hyperlipidemia (as indicated by high or increasing lipid concentrations) is found in an 
individual taking a drug that may cause or increase cholesterol (e.g., colchicine) 
Hypermagnesemia (as indicated by a high or increasing magnesium concentration) is found in 
an individual taking a drug that may cause or increase magnesium (e.g., magnesium 
supplements) 
Hypernatremia (as indicated by a high or increasing sodium concentration) is found in an 
individual taking a drug that may cause or worsen hypernatremia (e.g., prednisone) 
Hypertriglyceridemia (as indicated by a high or increasing triglyceride concentration) is found 
in an individual taking a drug that may cause or increase triglyceride (e.g., cyclosporine) 
Hyperuricemia (as indicated by a high or increasing uric acid concentration) is found in an 
individual taking a drug that may increase uric acid (e.g., nicotinic acid) 
Hypoalbuminemia (as indicated by a low or decreasing albumin concentration) is found in an 
individual taking a drug that may decrease albumin by causing anorexia (e.g., 
acetylcholinesterase inhibitors) 
Hypocalcemia (as indicated by a low or decreasing calcium concentration) is found in an 
individual taking a drug that may cause or worsen hypocalcemia (e.g., valproic acid) 
Hypoglycemia (as indicated by a low or decreasing glucose concentration) is found in an 
individual taking a drug that may cause or worsen hypoglycemia (e.g., insulin) 
Hypokalemia (as indicated by a low or decreasing potassium concentration) is found in an 
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individual taking a drug that may cause or worsen hypokalemia (e.g., diuretics) 
Hypomagnesemia (as indicated by a low or decreasing magnesium concentration) is found in an 
individual taking a drug that may cause or worsen hypomagnesemia (e.g., thiazide diuretics) 
Hyponatremia (as indicated by a low or decreasing sodium concentration) is found in an 
individual taking a drug that may cause or worsen hyponatremia (e.g., selective serotonin 
reuptake inhibitors) 
Hypophosphatemia (as indicated by a low or decreasing phosphate concentration) is found in an 
individual taking a drug that may cause or worsen hypophosphatemia (e.g., sorbitol,) 
Leukocytosis (as indicated by a high or increasing white blood cell count) is found in an 
individual taking a drug that may cause or worsen leukocytosis (e.g., etanercept) 
Leukopenia (as indicated by a low or decreasing white blood cell count) is found in an 
individual taking a drug that may cause or worsen leukopenia (e.g., beta-lactam antibiotics) 
Subtherapeutic concentration (below lower limit of normal range) of thyroid-stimulating 
hormone (TSH)  elevated concentration of thyroxine (T4) is found in an individual taking a 
drug that may cause hyperthyroidism (e.g., amiodarone) 
Supratherapeutic concentration (above upper limit of normal range) of TSH or decreased 
concentration of T4 is found in an individual taking a drug that may cause hypothyroidism 
(e.g., amiodarone) 
Supratherapeutic activated partial thromboplastin time (PTT) is found in an individual taking 
heparin 
Supratherapeutic international normalized ratio (INR) is found in an individual taking warfarin 
Thrombocytopenia (as indicated by a low or decreasing platelet count) is found in an individual 
taking a drug that may cause or worsen thrombocytopenia (e.g., clopidogrel) 
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Thrombocytosis (as indicated by a high or increasing platelet count) is found in an individual 
taking a drug that may cause or worsen thrombocytosis (e.g., beta-lactam antibiotics) 
 
Medication Concentrations 
Acetaminophen concentration is supratherapeutic in an individual taking acetaminophen 
Aminoglycoside peak or trough concentration is supratherapeutic in an individual taking an 
aminoglycoside antibiotic (e.g., amikacin, gentamicin, or tobramycin) 
Carbamazepine concentration is supratherapeutic in an individual taking carbamazepine 
Digoxin concentration is supratherapeutic in an individual taking digoxin 
Disopyramide (Norpace) concentration is supratherapeutic in an individual taking disopyramide  
Lithium concentration is supratherapeutic in an individual taking lithium 
Phenobarbital concentration is supratherapeutic in an individual taking phenobarbital  
Phenytoin concentration is supratherapeutic in an individual taking phenytoin 
Primidone (Mysoline) concentration or phenobarbital concentration is supratherapeutic in an 
individual taking primidone 
Procainamide concentration or N-acetylprocainamide (NAPA) concentration is supratherapeutic 
in an individual taking procainamide 
Quinidine concentration is supratherapeutic in an individual taking quinidine 
Salicylate (aspirin, salsalate, or choline magnesium trisalicylate) concentration is 
supratherapeutic in an individual taking salicylate 
Theophylline trough concentration is supratherapeutic in an individual taking theophylline  
Tricyclic antidepressant (e.g., amitriptyline, desipramine, or imipramine) concentration is 
supratherapeutic in an individual taking a tricyclic antidepressant 
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Valproic acid concentration is supratherapeutic in an individual taking valproic acid 
Vancomycin peak or trough concentration is supratherapeutic in an individual taking 
vancomycin 
 
Antidotes/Tracer Medications 
Anticonvulsant (e.g., benzodiazepine or phenytoin) is given to an individual taking a drug that 
may cause seizures (e.g., tramadol) 
Antidiarrheal (e.g., loperamide, diphenoxylate, or bismuth) is given to an individual taking a 
drug that may cause diarrhea (e.g., laxatives) 
Antiemetic (e.g., ondansetron, promethazine, or prochlorperazine) is given to an individual 
taking a drug that may cause nausea (e.g., opioid analgesics) 
Antifungal (e.g., clotrimazole, fluconazole, miconazole, or nystatin) is given to an individual 
taking a drug that may cause oral or vaginal candidiasis (e.g., antibiotics) 
Antihistamine (e.g., diphenhydramine or hydroxyzine) is given to an individual taking a drug 
that may cause a drug-induced rash (e.g., beta-lactam antibiotics) 
Atropine is given to an individual taking a drug that may cause bradycardia (e.g., beta-blockers) 
Benztropine (Cogentin), diphenhydramine, or trihexyphenidyl (Artane) is given to an individual 
taking a drug that may cause extrapyramidal symptoms (e.g., metoclopramide) 
Dextrose 50%, glucagon, or liquid glucose is given to an individual taking a drug that may 
cause hypoglycemia (e.g., insulin) 
Digoxin immune Fab (Digibind) is given to an individual whose digoxin concentration is 
supratherapeutic 
Epinephrine is given to an individual taking a drug that may cause an anaphylactic reaction 
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(e.g., aspirin) 
Flumazenil (Romazicon) is given to an individual taking a benzodiazepine (e.g., lorazepam) 
Lepirudin (Refludan) is given to an individual taking a drug that may cause heparin-induced 
thrombocytopenia 
Lidocaine is given to an individual taking an antiarrhythmic agent (e.g., procainamide) 
Metronidazole (oral) or vancomycin (oral) is given to an individual who has recently taken a 
drug that may cause pseudomembranous colitis (e.g., fluoroquinolone antibiotic) 
Naloxone (Narcan) is given to an individual taking an opioid analgesic (e.g., morphine) 
Phytonadione (Vitamin K) is given to an individual taking warfarin 
Protamine sulfate is given to an individual taking heparin 
Sodium polystyrene is given to an individual taking a drug that may cause hyperkalemia (e.g., 
potassium sparing diuretics) 
Steroids (oral) are given to an individual taking a drug that may cause a drug-induced rash (e.g., 
beta-lactam antibiotics) 
Steroids (topical) are given to an individual taking a drug that may cause a drug-induced rash 
(e.g., aspirin) 
 
Resident Assessment Protocols (RAPs) 
Activities of Daily Living Function RAP is triggered in an individual taking a drug (e.g., 
barbiturates) that may impair or worsen activities of daily living (bed mobility, transfers, 
eating, toilet use, or ambulation)  
Behavioral Symptoms RAP is triggered in an individual taking a drug (e.g., anticholinergics 
agents) that may cause or worsen behavioral symptoms (wandering, being verbally abusive, 
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being physically abusive, being socially inappropriate, or resisting care)  
Cognitive Loss RAP is triggered in an individual taking a drug (e.g., benzodiazepines) that may 
cause or worsen cognitive impairment (changes in level of consciousness, cognitive skills for 
daily decision-making, short-term or long-term memory, thinking, awareness, or recall)  
Dehydration/Fluid Maintenance RAP is triggered in an individual taking a drug (e.g., diuretics) 
that may cause or worsen dehydration (fluid loss exceeding the amount of fluid intake) 
Delirium RAP is triggered in an individual taking a drug (e.g., anticholinergic agents) that may 
cause or worsen delirium (periodic disordered thinking or awareness) 
Falls RAP is triggered in an individual taking a drug (e.g., opioid analgesics) that may cause or 
worsen falls (falls with or without injury)  
Mood State RAP is triggered in an individual taking a drug (e.g., beta-blockers) that may cause 
or worsen mood states (depression, anxiety, sad mood, or sleep cycle issues) 
Nutritional Status RAP is triggered in an individual taking a drug (e.g., acetylcholinesterase 
inhibitors) that may cause or worsen weight loss (chewing, swallowing, oral pain, weight 
changes, or dysgeusia) 
Urinary Incontinence RAP is triggered in an individual taking a drug (e.g., diuretics) that may 
cause or worsen urinary incontinence (control of urinary bladder function or bowel 
movements) 
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APPENDIX B 
Naranjo’s Causality Algorithm (refer to detailed instructions): 
 Yes No 
1.  Are there previous conclusive reports of this 
reaction? 
DK 
+1 0 0 
2.  Did the adverse event appear after the 
suspected drug was administered? 
+2 -1 0 
3.  Did the adverse reaction improve when the 
drug was discontinued OR was a specific 
antagonist (i.e., antidote) was administered? 
+1 0 0 
4.  Did the adverse reaction reappear when the 
drug was re-administered? 
+2 -1 0 
5.  Are there alternative causes (other than the 
drug) that could, on their own, have caused 
the reaction? 
-1 +2 0 
6.  Did the reaction reappear when a placebo 
was given? 
-1 +1 0 
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7.  Was the drug detected in the blood (or other 
fluids) in concentrations known to be toxic 
(i.e., above normal reference range)? 
+1 0 0 
8.  Was the reaction more severe when the 
dose was increased or less severe when it 
was decreased? 
+1 0 0 
9.  Did the patient have a similar reaction to the 
same or similar drugs in any previous 
exposure? 
+1 0 0 
10.  Was the adverse event confirmed by any 
objective evidence (i.e., laboratory data)? 
+1 0 0 
POINT TOTAL=  
Scoring: Doubtful < 0; Possible 1-4; Probable 5-8; Definite > 9 
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